Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Organic pressurized fluid

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424043000 - EFFERVESCENT OR PRESSURIZED FLUID CONTAINING

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
424047000 Topical live body grooming or adorning aid (e.g., hair spray, antiperspirant, etc.) 73
424046000 Powder or dust containing 26
Entries
DocumentTitleDate
20080279788Propellant for Dosing Aerosols Comprising Packagings - The invention relates to a pharmaceutical product comprising a dosing aerosol containing a propellant, an effective quantity of adsorbent, a pharmaceutically active substance, substance formulation or substance mixture, and a packaging enclosing the adsorbent and the dosing aerosol with the pharmaceutically active substance, substance formulation or substance mixture.11-13-2008
20090220435TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS - Compounds and components including sequences for mucosal epithelial transport of an active agent are given. Tight junction modulating peptide components are described for use in transport and delivery. Permeability can be enhanced with reversibility. Compounds and components for enhanced delivery may be peptide or protein variants, conjugates, or other analog types and structures.09-03-2009
20090053148TOLL LIKE RECEPTOR MODULATORS - The invention relates to TLR9 antagonist compounds and their therapeutic or prophylactic use. The invention provides novel immune regulatory oligonucleotides and immunomers as antagonist of TLRs and methods of use thereof. These immune regulatory oligonucleotides have unique sequences that suppress, without completely ablating, TLR-mediated signaling in response to a TLR ligand or TLR signaling agonist. The methods may have use in the prevention and treatment of autoimmunity, inflammation, inflammatory bowel disease, lupus, allergy, asthma, infection, sepsis, cancer and immunodeficiency.02-26-2009
20080260656Ungual/periungual compositions comprising morpholine compounds and water-soluble film-forming agents - Pharmaceutical compositions suited for ungual and periungual application and useful for the treatment of dermatological conditions/afflictions, in particular onychomycosis, contain an anti-mycotic agent of the family of the morpholines and a water-soluble film-forming agent.10-23-2008
20080260654Sustained Release Composition of Protein Drug - Disclosed is a sustained release composition of a protein drug. The composition comprises a carrier substrate and a protein drug incorporated in the carrier substrate. The carrier substrate is consisting essentially of a hyaluronic acid or its salts, an amino acid, and a polyalkyl oxide.10-23-2008
20100015061 Pharmaceutical Compositions Based on Anticholinergics and Andolast - The present invention relates to novel pharmaceutical compositions based on anticholinergics and andolast, processes for preparing them and their use in the treatment of respiratory diseases.01-21-2010
20090123391Novel Formulations - A pharmaceutical aerosol formulation includes a therapeutically effective amount of particulate medicament of formula (I) or a solvate thereof, a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoro-n-propane or mixtures thereof, and a biocompatible polymer comprising one or more compounds of formula (II)05-14-2009
20090123390COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL INFLAMMATION - Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.05-14-2009
20090123389Methods for modulating Th17 cell development in the treatment and prevention of cellulite - This invention relates generally to methods and compositions for modulating the development of Th17 cells for use, for example, in the treatment of cellulite.05-14-2009
20090191135METHODS FOR THE DISPERSION OF WATER-SOLUABLE OR HYDROPHILIC SUBSTANCES IN A SUPERCRITICALLY PRESSURIZED FLUID - A method for encapsulating an active principle by dispersing the active principle in a supercritical fluid by adding a surfactant to the fluid. The surfactant is a block copolymer having at least one CO07-30-2009
20090191134Stable aerosol pharmaceutical formulations - The present invention provides a stable aerosol pharmaceutical formulation of a beta-agonist, an anticholinergic, or a combination thereof in combination with a cosolvent and optionally a surfactant. The invention also provides a method of making the stable aerosol pharmaceutical formulation and methods of treating bronchoconstriction, asthma and related conditions with the stable aerosol pharmaceutical formulation of the present invention.07-30-2009
20090191133MODULATION OF STAT 6 EXPRESSION FOR THE TREATMENT OF AIRWAY HYPERRESPONSIVENESS - Disclosed herein are compounds, compositions and methods for modulating the expression of STAT 6 in a cell, tissue, or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of STAT 6, airway hyperresponsiveness, and/or pulmonary inflammation. 07-30-2009
20100158818ANTIMICROBIAL N-CHLORINATED COMPOSITIONS - The present application relates to N-chlorinated cationic compounds of Formula I06-24-2010
20100158819Calcium Glycerophosphate for Treating and Preventing Respiratory Diseases or Conditions - Calcium glycerophosphate is found to be effective in treating and preventing a disease, disorder and/or condition of the respiratory system. The disease, disorder and/or condition is related to an obstructive or a restrictive condition of the respiratory airway. The disease, disorder and/or condition can be a respiratory airway inflammatory disease, a respiratory airway stenosis or a nasal cavity inflammatory disease, such as an asthma, a chronic obstructive pulmonary disease (COPD), an emphysema, a reactive airway disease (RADS), rhinitis, bronchitis, bronchiolitis, congestion, sinusitis, tonsillitis, or laryngitis, post-nasal drip (PND) and a related complication thereof, inflamed degranulating and non-degranulating mast cell activity, any irritation occasioning mucus secretion from goblet cells breathing difficulty, restriction, obstruction; airways constriction or closure or mucus interference with air passage; sleep apnea, snoring, inflammatory or non-inflammatory responses to an airborne or non-airborne allergen or irritant; nasal or non-nasal airway inflammation or irritation caused by a problem in any area of the body; and a physical damage to the respiratory system. Methods, compositions and devices are described for using calcium glycerophosphate to treat and prevent the disease, disorder and/or condition of the respiratory system.06-24-2010
20130078191AEROSOL COMPOSITION - There is provided an aerosol composition which is high in fire safety and assures easy emulsification of an aqueous concentrate and a liquefied gas. The aerosol composition comprises 10 to 60 wt % of an aqueous concentrate and 40 to 90 wt % of a liquefied gas, and is obtained by emulsifying the aqueous concentrate and the liquefied gas, wherein the liquefied gas comprises a heavy liquefied gas (a) having a liquid density at 20° C. of from 1.15 to 1.30 (g/ml).03-28-2013
20130084251TREATMENT OF ACTIVE INFECTIONS AND RELATED COMPOSITIONS - The present invention is directed to the treatment of infections and the associated symptoms of sinusitis, rhinitis and related neurological disorders of the cranial cavity and facial tissue. More specifically, the present invention is directed to aerosols that are used to treat infections and the associated symptoms of sinusitis, rhinitis and related neurological disorders of the cranial cavity and facial tissue, compositions from which the aerosols are generated and methods of generating the aerosols. In an aerosol aspect of the present invention, an aerosol for delivery to the sinus cavity of a patient is provided. The aerosol includes at least: a) one or more compounds selected from antibiotics, antifungals, leukotriene antagonists, anti-TNF compounds, antihistamines, steroidal antiinflammatories, mucolytics, estrogen, progesterone and related hormones; and, b) water. The compounds are present in the water at a concentration ranging from 0.01 mg/kg to 1000 mg/kg, and the aerosol does not contain a surfactant.04-04-2013
20100015064FOAMABLE COMPOSITION FOR KILLING ARTHROPODS AND USES THEREOF - A foamable composition for killing arthropods and their eggs, such as lice or ticks and nits is disclosed. The composition for killing arthropods contains as active ingredient more than 50% by weight of one or more saturated linear or branched hydrocarbons and as a stabilizing agent one or more linear or branched siloxanes. Preferably, the composition is a non-aqueous foamable composition, having more than 50% by weight of one or more saturated linear hydrocarbons, preferably saturated linear C01-21-2010
20130039863METHODS OF CONTROLLING THE BREEDING BEHAVIOR OF BUTTERFLIES - Methods of controlling the feeding and/or breeding behavior of a target insect are disclosed in which a host plant is provided a substantial distance from a plant of interest, chemical attractant that induces the target insect to lay eggs on the host plant is applied to the host plant, application of the chemical attractant to the host plant is repeated as required to induce residual target-insect populations to lay eggs on the host plant, and wherein the behavior is controlled when a substantial number of off-spring belonging to subsequent generations themselves mature and display a preference for laying eggs on the same type of host plant on which they were reared without further application of the chemical attractant is provided. Also disclosed are methods of deterring target insect feeding and breeding on plants of interest by applying toxic plant extract to the plants of interest.02-14-2013
20100111878SKIN-CARE COMPOSITIONS AND USES THEREOF - Composition of a Dead Sea extract and at least one plant extract of a Himalayan origin are provided for topical applications.05-06-2010
20100104515USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS - There is provided the use as reducing agents of alpha-hydroxycarbonyl compounds capable of forming cyclic dimers. There is also provided corresponding methods of reducing reducible compounds, particularly reduction-activated prodrugs. Examples of the alpha-hydroxycarbonyl compounds used are dihydroxyacetone, glycolaldehyde, glyceraldehyde, erythrose, xylulose, erythrulose or 3-hydroxy-2-butanone.04-29-2010
20100104516USE OF FLAGELLIN TO PREVENT AND TREAT GRAM NEGATIVE BACTERIAL INFECTION - The disclosure describes use of flagellin polypeptides to induce tolerance to gram negative bacteria, such as 04-29-2010
20090155187DRUG FOR INHIBITING VASCULAR INTIMAL HYPERPLASIA - To provide an intimal hyperplasia inhibitor useful for prevention of restenosis after percutaneous transluminal coronary angioplasty (PTCA) or vascular stent placement or treatment of its progress.06-18-2009
20090155186Compositions and methods for treating inflammatory conditions - The present invention relates to compositions containing signal transduction modulator compounds, to methods for treating or preventing inflammation, or promoting healthy joints, using the compounds and to kits for the same.06-18-2009
20100040559Use of a Pharmaceutical Composition Comprising an Anticholinergic for Killing Microorganisms and for Treating Respiratory Tract Infections - The present invention relates to the use of a compound of the formula 1 in which X02-18-2010
20100040558GREEN TEA POLYPHENOL ALPHA SECRETASE ENHANCERS AND METHODS OF USE - The subject invention concerns materials and methods for treating or preventing a neurodegenerative condition or disease associated with β-amyloid peptide deposition in neural tissue in a person or animal by administering a therapeutically effective amount of a polyphenol, or an analog, isomer, metabolite, or prodrug thereof, that increases expression or activity of a protein that exhibits α-secretase activity. The subject invention also provides methods to increase α-secretase expression and/or activity in cells by administering polyphenol flavonoids like (−)-epigallocatechin-3-gallate (EGCG) and epicatechin (EC), two polyphenols derived from green tea and other plants and that can be produced synthetically. Furthermore, there are provided methods to decrease or inhibit the production of Aβ02-18-2010
20100040560AEROSOLIZED FLUOROQUINOLONES AND USES THEREOF - Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.02-18-2010
20080206157CEREBRAL PROTECTION WITH A XENON-CONTAINING GAS - Xenon or xenon-containing gases and, where appropriate, an NO source are employed as medicament for cerebral protection. Cerebral protection is defined as reducing or preventing impairments of cerebral function of various causes, but especially secondary to perfusion impairments of unclear etiology. The medicament can be used for cerebral protection for the prophylaxis of impairments of cerebral perfusion and for therapy after cerebral disorders have occurred, irrespective of the cause (e.g. cognitive, sensory or motor in nature).08-28-2008
20090074677Neuroactive steroid compositions and methods of use therefor - Provided are methods for ameliorating a symptom of a neuropsychiatric disorder in a subject. Also provided are methods for ameliorating at least one physical symptom or at least one psychological symptom resulting from tobacco cessation in a subject, methods for ameliorating a symptom of Alzheimer's disease or other cognitive disorder in a subject, methods for ameliorating a symptom of schizophrenia, schizoaffective disorder, or other psychotic disorder in a subject, methods for ameliorating a symptom of a depressive disorder in a subject, methods for ameliorating a symptom of bipolar disorder in a subject, methods for ameliorating a symptom of post-traumatic stress disorder or other anxiety disorder in a subject, methods for predicting a predisposition to suicide, suicidal ideation, suicidal behavior, or a combination thereof in a subject, methods for ameliorating a symptom of a pain disorder in a subject, methods for ameliorating a neurodegenerative disorder in a subject, methods for ameliorating a symptom of traumatic brain injury in a subject, methods for ameliorating a sleep disorder in a subject, and methods for improving cognitive functioning in a subject. In some embodiments, the methods include administering to a subject in need thereof an effective amount of a neuroactive steroid composition comprising pregnenolone (PG), allopregnanolone (ALLO), dehydroepiandrosterone (DHEA), pharmaceutically acceptable salts thereof, derivatives thereof, or combinations thereof.03-19-2009
20100143266METHODS FOR REDUCING ALLERGIES CAUSED BY ENVIRONMENTAL ALLERGENS - Compositions suitable for reducing symptoms of an allergic response to environmental allergens comprising molecules that specifically inhibit the ability of the allergen to bind to mast cells in an animal predisposed to having an allergic response to the allergen and methods for reducing such symptoms comprising contacting a source of the environmental allergen with such compositions. Kits, packages, medicaments, and means of communicating about the compositions and methods are also provided.06-10-2010
20100329996Novel Combination of Therapeutic Agents - Novel combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist and/or a corticosteroid for inhaled administration via the nose or mouth, and methods of using them are provided herein.12-30-2010
20130028845LEVALBUTEROL SALT - Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.01-31-2013
20090317337AEROSOL FORMULATION FOR INHALATION CONTAINING AN ANTICHOLINERGIC AGENT - The invention relates to specific aqueous aerosol formulations that are devoid of propellant, containing one or more anticholinergic agents of formula (1), in which X represents an anion, and containing at least one pharmacologically compatible organic acid and optionally additional pharmacologically compatible adjuvants and/or complexing agents. The cation of formula (1′) is contained in the preparation at a concentration of between 32 and 54 mg per 100 ml of medicament preparation.12-24-2009
20090304604PULMONARY DELIVERY OF ALPHA-1 PROTEINASE INHIBITOR - The present invention relates to a system that includes a pharmaceutical composition of a purified, stable, active alpha-1 proteinase inhibitor (API) in a form of a ready to use sterile solution and an inhalation nebulizer, and to methods of use thereof for treating pulmonary diseases.12-10-2009
20130071337Interomone Compositions and Their Use to Modify Behavior in Different Vertebrate Species - A composition comprising an interomone is described for the modification of undesirable or harmful stress-related behaviors or other behaviors or physiology in a variety of vertebrate species, as well as methods of using the compositions in vertebrates from a species different than the species in which the interomone is a naturally occurring pheromone.03-21-2013
20090092559Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant - The invention relates to pressurized gas formulations for dosage aerosols, in which a medicament is formulated suspended in TG 227 ea (1,1,1,2,3,3,3-heptafluoropropane) and/or TG 134 a (1,1,1,2-tetrafluoroethane) as a propellant, and to their use for producing a medicament. The aerosol is preferably an inhalation aerosol.04-09-2009
20090092558MEDICAMENTS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE - A pharmaceutical composition comprising a compound of formula 104-09-2009
20110014135VITAMIN FORMULATION - A pharmaceutical aerosol foam composition, comprising: an effective amount of a pharmaceutically active ingredient, wherein said pharmaceutically active ingredient is a vitamin or analogue thereof; an occlusive agent; an aqueous solvent; an organic cosolvent; wherein the pharmaceutically active ingredient is insoluble in both water and the occlusive agent; and the occlusive agent being present in an amount sufficient to form an occlusive layer on the skin, in use. In a second embodiment, an oil-in water emulsion having a vitamin, an occlusive agent; an aqueous solvent; and an organic cosolvent, wherein the occlusive agent is present in an amount sufficient to form an occlusive layer on the skin.01-20-2011
20110014134SUSPENSION AEROSOL FORMULATIONS OF PHARMACEUTICAL PRODUCTS - Pharmaceutical preparations for producing powder aerosols using propellant gases which use TG 227, and possibly also TG 11, TG 12, TGH 114, propane, butane, pentane or DME.01-20-2011
20090280068POLYMORPH OF 8-HYDROXY-5-[(1R)-1-HYDROXY-2-[[(1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL]AM- INO]ETHYL]-2(1H)-QUINOLINONE MONOHYDROCHLORIDE - Crystal form D of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]-amino]ethyl]-2(1H)-quinolinone monohydrochloride is highly crystalline, easy to prepare, and stable.11-12-2009
20090196833COMPOSITIONS COMPRISING TOPICAL DPD INHIBITORS AND METHODS OF USING SAME IN THE TREATMENT OF HAND-FOOT SYNDROME - Topical formulations comprising inhibitors of dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP) and/or uridine phosphorylase (UP) enzyme inhibitors are provided for the treatment of hand-foot syndrome (HFS) in cancer patients undergoing treatment with 5-FU and 5-FU prodrugs.08-06-2009
20090238771PHARMACEUTICAL FORMULATIONS - An aspect of the present invention provides for a medicament including a solution containing pleconaril or a pharmaceutically acceptable salt thereof, wherein at least one solvent comprising said solution is a pleconaril-dissolving glyceride oil, and the solution is suitable for inhalation administration as an aerosol mist.09-24-2009
20090238770Organic compounds - A medicament comprising, separately or together, (A) a compound of formula I09-24-2009
20130101525VITAMIN FORMULATION - A pharmaceutical aerosol foam composition, comprising: an effective amount of a pharmaceutically active ingredient, wherein said pharmaceutically active ingredient is a vitamin or analogue thereof; an occlusive agent; an aqueous solvent; an organic cosolvent; wherein the pharmaceutically active ingredient is insoluble in both water and the occlusive agent; and the occlusive agent being present in an amount sufficient to form an occlusive layer on the skin, in use. In a second embodiment, an oil-in water emulsion having a vitamin, an occlusive agent; an aqueous solvent; and an organic cosolvent, wherein the occlusive agent is present in an amount sufficient to form an occlusive layer on the skin.04-25-2013
20090232744Macrolide compositions having improved taste and stability - The invention provides an aqueous pharmaceutical composition for administration as an aerosol to the respiratory tract, nose or oropharyngeal region comprising (i) a macrolide having a poor taste and poor chemical stability in aqueous solution; (ii) at least one salt selected from the group consisting of sodium gluconate, sodium aspartate, sodium acetate, sodium lactate, sodium succinate, sodium maleate, magnesium gluconate, magnesium aspartate, magnesium citrate, magnesium acetate, magnesium lactate, magnesium succinate, and magnesium maleate; or mixtures thereof and (iii) a taste-masking agent different from said salt; wherein (a) the concentration of said macrolide in the composition is in the range of about 0.25 wt.-% to about 15 wt.-%; (b) the molar ratio of said macrolide:said salt is in the range from about 1:0.5 to about 1:100; (c) the pH of the composition is in the range of about 3 to 9; and (d) the osmolality of the composition is in the range of about 150 mOsmol/kg to about 1500 mOsmol/kg. The invention further provides a method of generating an aerosol, preferably by means of a nebuliser, which uses such an aqueous pharmaceutical composition. The macrolide may be used alone or in combination with other drugs. The composition is suitable to treat inflammatory disorders and/or infections of the respiratory tract. It has an improved taste and stability.09-17-2009
20100028267Compositions and methods for reducing capillary permeability - The invention generally relates to compositions and methods for reducing capillary permeability. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.02-04-2010
20080305050Analysis of P. aeruginosa infection in patients - The present invention relates to methods for detecting 12-11-2008
20080274061Method for Treating a Restless Limb Disorder - A method for treating a restless limb disorder such as restless legs syndrome in a subject comprises administering, transmucosally in the oronasopharyngeal chamber of the subject, one or more doses of rotigotine or a pharmaceutically acceptable salt, prodrug or metabolite thereof, wherein each such dose comprises an amount effective to reduce occurrence and/or severity of one or more symptoms of the disorder, but wherein the total of all such doses in a 24-hour period does not exceed about 11-06-2008
20090123388Prodrugs of Short-Chain Fatty Acids and Treatment Methods - Prodrugs made up of biologically-active short-chain fatty acids or derivatives thereof conjugated to neutral or cationic amino acids capable of intracellular transport by ATB05-14-2009
20090098062Activated Peroxide Solutions and a Process for the Preparation thereof - The present invention discloses an activated biocidal aqueous solution containing hydrogen peroxide (activated peroxide solution) obtainable by subjecting an initial solution of hydrogen peroxide in water to a non-thermal electrical discharge process, such as a glow discharge plasma or a corona discharge. The resulting activated peroxide solution containing 0.05 to 20% (w/w) hydrogen peroxide has a pH in the range of 2 to 4, an oxidation-reduction potential (ORP) in the range of 400 to 600 mV, and the solution when having a peroxide content in the range of 0.05% to 0.5% (w/w) has a conductivity in the range of 100 to 500 μSiemens/cm, the solution when having a peroxide content in the range of 0.1% to 5% (w/w) has a conductivity in the range of 100 to 450 μSiemens/cm, and the solution when having a peroxide content in the range of 5% to 20% (w/w) has a conductivity in the range of 100 to 350 μSiemens/cm. The pH, ORP and conductivity are measurable under conditions essentially without the presence of additional compounds in the solution. The biocidal activity of the solution is substantially higher than that of a common peroxide solution. The biocidal solution may be used for any purpose where disinfecting and/or sanitizing and/or cleaning and/or bleaching and/or preservative activity is required. The present invention further discloses a non-thermal electrical discharge process, in particular a pulsed corona induced low frequency pulsed DC plasma discharge process, for the preparation of the activated peroxide solution.04-16-2009
20090068118DEVICE FOR DELIVERY OF A FOAMABLE COMPOSITION - A device for delivery of a foamable composition to a body cavity includes a pressurized composition reservoir; a hollow body having a longitudinally extending wall and having at least one aperture provided through a wall of said body, the proximal end in fluid communication with the reservoir for receiving a foamable composition from said composition reservoir; and an actuator operatively connected to the composition reservoir for effecting release of a foamable composition from said composition reservoir into a body cavity through said hollow body; wherein said body has a length less than about 125 mm and internal diameter in the range of about 1.5 mm to about 3.5 mm, wherein said length and internal diameter are selected to provide a delivery of at least about 70% of the foamable composition during operation. The foam delivery device can have multiple apertures.03-12-2009
20100310477Pharmaceutical compositions based on anticholingerics and additional active ingredients - A pharmaceutical composition comprising an anticholinergic and at least one additional active ingredient selected from among corticosteroids, dopamine agonistes, PDE-IV inhibitors, NK1-antagonists, endothelin antagonists, antihistamines, and EGFR-kinase inhibitors, processes for preparing them and their use in the treatment of respiratory diseases.12-09-2010
20090136430Antihistamine/Corticosteroid preparations for the treatment of atopic dermatitis - It has been found that the combination of an antihistamine with a corticosteroid is more effective in the treatment of atopic dermatitis than either one used separately. The synergistic effect in some cases results in the disappearance of the atopic dermatitis lesion within one to five days with little or no relapse. Compositions and the methods of utilizing these preparations are disclosed.05-28-2009
20120189555METHODS AND COMPOSITIONS FOR PREVENTION OR TREATMENT OF RSV INFECTION - Methods and compositions are provided for the prevention or treatment of RSV infection in a human. The methods include administering one or more doses of a composition comprising an siRNA. The dose can be formulated for topical or parenteral administration. Topical administration includes administration as a nasal spray, or by inhalation of respirable particles or droplets. The siRNA comprises a sense strand of ALN-RSV01 and an antisense strand of ALN-RSV01.07-26-2012
20090016969PHARMACEUTICAL COMPOSITION FOR TOPICAL APPLICATION OF POORLY SOLUBLE COMPOUNDS - The present invention provides a formulation which contains a poorly water soluble pharmaceutically active compound at a concentration of 50 mg per 100 g formulation or above. The solubility is achieved by a mixture of solvents as described herein. Moreover the formulation as described herein may be used as a base formulation to generate a cream, an ointment, a spray, a foam or an oleogel.01-15-2009
20100266511PHARMACEUTICAL FOAM - The present invention provides various pharmaceutically active topical delivery compositions. In particular, compositions of the present invention are present in a pressurized container comprising a quick-breaking alcoholic foaming agent, such that when the composition is released, i.e., dispensed, from the pressurized container, a quick-breaking temperature sensitive foam is formed. In addition, the present invention provides various aspects related to such compositions, including methods for modulating a foam characteristic, methods for improving the shelf-life of a pharmaceutically active compound, methods for the percutaneous treatment of various diseases, infections, and illnesses, and methods for evaluating foam characteristics.10-21-2010
20100098641Monophosphates as Mutual Prodrugs of Anti-Inflammatory Signal Transduction Modulators (AISTM's) and Beta-Agonists for the Treatment of Pulmonary Inflammation and Bronchoconstriction - A mutual prodrug of an AISTM and a β-agonist in formulation for delivery by aerosolization to inhibit pulmonary inflammation and bronchoconstriction is described. The mutual prodrug is preferably formulated in a small volume solution (10-500 μL) dissolved in a quarter normal saline having pH between about 5.0 and 7.0 for the treatment of respiratory tract inflammation and bronchoconstriction by an aerosol having mass median average diameter predominantly between about 1 to 5μ, produced by nebulization or by dry powder inhaler.04-22-2010
20100266512CROSSLINKED HYALURONIC ACID IN EMULSION - The present invention relates to methods of producing crosslinked hyaluronic acid microbeads, as well as the produced microbeads, said method comprising the steps of: (a) providing an aqueous alkaline solution comprising hyaluronic acid, or a salt thereof; (b) forming microdroplets having a desired size from the mixed solution of step (a) in an organic or oil phase to form a water in organic or water in oil (VWO) emulsion, wherein the amount of oil phase used is of from 20 to less than 50% by weight based on the sum of oil phase and water; (c) adding a solution comprising a crosslinking agent to the emulsion, whereby the reaction of hyaluronic acid with the crosslinking agent takes place to provide crosslinked hyaluronic acid microbeads; and (d) optionally working up the dispersion of crosslinked hyaluronic acid microbeads obtained in step (c).10-21-2010
20090104126Sulfamate Compounds and Uses Thereof - A sulfamate compound corresponding to Formula I04-23-2009
20080206159COMPOSITIONS WITH MODULATING AGENTS - The present invention relates to a waterless composition and foam as a vehicle in which an active pharmaceutical or cosmetic agent, when added is stable or stabilized by or its destabilization is impeded by the presence of a modulating agent. The pharmaceutical or cosmetic composition and foam, includes: a waterless solvent, a modulating agent and one or more active pharmaceutical or cosmetic agents. The present invention also relates to a method of treatment administering the waterless composition and foam.08-28-2008
20090053149SURFACTANT-BASED ANTIMICROBIAL SOLUTION FOR INHALATION - A surfactant can be added, safely and effectively, to a drug solution containing any antimicrobial agent, such as an antibiotic like tobramycin, that is suitable for administration to the lungs via inhalation. Thus, when an aerosolized drug solution includes surfactant, Marangoni flows cause the drug particles, once deposited in the lungs, to spread over a wider surface area, thereby ensuring greater antimicrobial efficacy. A solution that contains, for example, an antibiotic and tyloxapol or another surfactant providing a similar surface tension to the composition is optimally delivered by the functional combination of a breath-actuated nebulizer and a high-flow compressor.02-26-2009
20090087388IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE - The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.04-02-2009
20120003161USE OF INOSITOL-TRIPYROPHOSPHATE IN TREATING TUMORS AND DISEASES - Inositol-tripyrophosphate is an allosteric effector of hemoglobin due to its ability to cross the plasma membrane of red blood cells and deliver oxygen to solid tumors, by lowering the oxygen affinity of the hemoglobin of red blood cells. The present invention is directed to the use of inositol-tripyrophosphate to reduce hemoglobin's affinity for oxygen in circulating red blood cells. The present invention is further directed to the use of inositol-tripyrophosphate to inhibit angiogenesis and enhance radiation sensitivity of hypoxic tumors. The present invention is further directed to the use of inositol-tripyrophosphate to enhance PO01-05-2012
20120189556PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND CORTICOSTEROIDS - A pharmaceutical composition comprising an anticholinergic and a steroid, optionally together with a pharmaceutically acceptable excipient, the anticholinergic and the steroid optionally in the form of their enantiomers, mixtures of their enantiomers, their racemates, their solvates, or their hydrates, processes for preparing them, and their use in the treatment of respiratory tract diseases.07-26-2012
20090202447INHALANT AEROSOL FORMULATIONS CONTAINING ETHANOL - The invention relates to inhalant, propellant-free aerosol formulations containing ethanol, said formulations having defined particle size distribution sizes.08-13-2009
20090098061SOLUTION FOR TISSUE ADHESION PREVENTION AND METHOD FOR TISSUE ADHESION PREVENTION - The objective of the invention is to provide a solution for tissue adhesion prevention and a method for tissue adhesion prevention that are applicable to general surgery and in which covering condition during surgery is stable and convenient. The invention is the solution for tissue adhesion prevention of which the active ingredient is trehalose. Also, it contains at least one or more among antioxidants, chelates, antiseptics, hemostatics, anti-inflammatory agents, and polysaccharides, mucopolysaccharides, salts of polysaccharides and salts of mucopolysaccharides having lubricating properties. This solution for tissue adhesion prevention is provided as any form of perfusion fluid, spray fluid, solution for spray or vaporization administration, foam-like aerosol preparation, injection solution for intravenous fluids, intravenous fluid.04-16-2009
20090280067CRYSTAL FORM OF 8-HYDROXY-5-[(1R)-1-HYDROXY-2-[[(1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL]AM- INO]ETHYL]-2(1H)-QUINOLINONE MONOHYDROCHLORIDE - Crystal form E of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]-amino]ethyl]-2(1H)-quinolinone monohydrochloride is highly crystalline, easy to prepare, and stable.11-12-2009
20110165097COMPOSITIONS FOR PERCUTANEOUS ADMINISTRATION - Compositions intended for the percutaneous administration of physiologically active agents, e.g. drugs or a veterinary agents, are disclosed. Sasd compositions are characterized by having an exeefenf long term efficacy due to their ability to form a long-lasting film on the skin.07-07-2011
20110165096Ficus Extracts Having Angiogenesis Ihibiting Activity And Methods Of Isolating And using The Same - The present invention is directed to methods for extracting and isolating extracts having angiogenesis inhibiting activity from a latex-containing portion of a 07-07-2011
20110165095COMPOSITION AND METHOD FOR THE INHIBITION OF POSTOPERATIVE ADHESIONS SEVERITY - The present invention refers to the use of growth factors, which are effective on mesothelial cell proliferation, used in a sterilized carboxymethylchitosan pharmaceutical composition employed to reduce postoperative adhesions severity. The present invention also provides a method to inhibit postoperative adhesions severity.07-07-2011
20110293534Aerosol can spray incorporating a nutritional cell scaffold for use as first aid treatment for wounds/burns and for use in cell therapy/tissue repair - A First Aid aerosol can spray using a propellant authorized for human use. Spray will be in the form of a ‘light emulsion’ for use on burns and wounds at incident sites. If propellant is not used, two of the spray constituents, namely sterile cornstarch granules, a nutritional cell scaffold and antibiotic(s) may be used for guided subcutaneous tissue repair. Specific cell culture techniques are described for both epidermal and dermal cells which are to be externally applied to aid wound healing of wider, deeper wounds/burns in terms of total body area affected.12-01-2011
20100221195SUBSTANTIALLY NON-AQUEOUS FOAMABLE PETROLATUM BASED PHARMACEUTICAL AND COSMETIC COMPOSITIONS AND THEIR USES - The present invention relates to stable substantially non-aqueous, non-alcoholic, non-silicone, foamable carrier compositions comprising petrolatum or mixtures thereof, at least one foam agent, at least one propellant, and with and without the addition of an active agent. The formulations may contain a solvent substantially miscible therein. The present invention further provides a method of treating, alleviating or preventing a disorder of mammalian subject in need thereof, comprising administering the above-mentioned compositions to an afflicted target site of said mammalian subject.09-02-2010
20100278755COMPOSITION CONTAINING P-MENTHANE-3, 8-DIOL AND ITS USE AS INSECT REPELLANT - An economical and simple method of producing para-menthane-3,8-diol in relatively high yield is disclosed. The product is useful as a repellent against noxious insects and other arthropods.11-04-2010
20110142767RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS - RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.06-16-2011
20090246149MEDICINAL AEROSOL FORMULATIONS - Use of particulate bulking agents having an extremely small mass median diameter of less than one micron, preferably less than 300 nm, in pharmaceutical aerosol formulations comprising a suspension of drug particles in a propellant. Examples of bulking agents include ascorbic acid, saccharides, polysaccharides, amino acids, organic and inorganic salts, urea, and propyliodone.10-01-2009
20100111879SACCHARIDE FOAMABLE COMPOSITIONS - A foamable composition, containing a saccharide for use in the treatment of various disorders including: water, a saccharide, about 0.2% to about 5% by weight of a surface-active agent, about 0.01% to about 5% by weight of at least one polymeric agent selected from a bio-adhesive agent, a gelling agent, a film forming agent and a phase change agent, and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.05-06-2010
20100034752INHALANT FORMULATIONS COMPRISING A BISPHOSPHONATE AND A PYRAZOLONE DERIVATIVE AND METHODS FOR USING THE SAME - The present invention provides for methods of administering by a pulmonary route a bisphosphonate active agent in combination with a pyrazolone derivative to a subject. Also provided are pharmaceutical compositions for use in practicing methods according to embodiments of the invention. The methods and compositions according to embodiments of the invention find use in a variety of different applications, including but not limited to, the treatment of bone absorption disease conditions.02-11-2010
20090148390JUCARA AND ACAI FRUIT-BASED DIETARY SUPPLEMENTS - The present invention relates to stable, palatable, freeze-dried, fruit-based dietary supplements. Specifically, the inventions relates to compositions of Açai fruit and Jucara fruit with high antioxidant capability and cyclooxygenase-inhibitory activity, and their uses. The invention further provides for methods of making stable, palatable, freeze-dried, fruit-based dietary supplements from Açai fruit and Jucara fruit.06-11-2009
20100202977Modulation of Stat 6 Expression for the Treatment of Airway Hyperresponsiveness - Disclosed herein are compounds, compositions and methods for modulating the expression of STAT 6 in a cell, tissue, or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of STAT 6, airway hyperresponsiveness, and/or pulmonary inflammation.08-12-2010
20110171142Metformin glycinate salt for blood glucose control - The present invention relates to metformin glycinate salt and pharmaceutical compositions thereof for the treatment of diabetes mellitus. The method includes administration of the metformin glycinate salt by various routes selected from oral, intravenous injectable, intramuscular injectable, nasal, intraperitoneal, or sublingual, in order to achieve a reduction in blood glucose levels. The invention further relates to the synthesis of a new 1,1-dimethylbiguanide glycinate salt, called Metformin Glycinate. The resulting salt exhibits advantages over other metformin salts. These advantages are due, in the first place, to the fact that the glycine counterion exhibits hypoglycemic effects by itself. Moreover, the salt exhibits more rapid absorption, reaching higher plasma concentrations than those produced with metformin hydrochloride.07-14-2011
20110150783AEROSOL FORMULATION FOR COPD - Stable aerosol solution formulations comprising glycopyrronium bromide are useful for administration to patients with COPD and other respiratory conditions.06-23-2011
20110085989NOVEL ANTIMICROBIAL PEPTIDES - This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against 04-14-2011
20090087387ACETALS OF NEPETALIC ACID AND METHOD OF PREPARATION - Disclosed are acetals of nepetalic acid. They may be prepared by reaction of an alcohol with nepetalic acid, and are useful as repellents for insects and arthropods, in addition to other uses.04-02-2009
20100080761Extracts of Isochrysis sp. - The present invention relates to extracts of 04-01-2010
20100080760Method, device, and system to control pH in pulmonary tissue of a subject - Methods, devices, and systems are provided which include an aerosol generator and a pharmaceutical composition including a membrane selective for a charged ion configured to achieve a selected pH of a pulmonary tissue in a subject. The methods, devices, or systems which include the membrane may be configured to alter selectivity for the charged ion in response to a sensed condition in the pulmonary tissue.04-01-2010
20090257957Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders - This invention provides specifically formulated LFA-1 antagonists or pharmaceutically acceptable salts thereof that are suitable for aerosolized delivery. In particular, the LFA-1 antagonists are particularly well suited for localized treatment by having a rapid systemic clearance rate. The invention also encompasses methods of treatment and prevention of immune related disorders using the LFA-1 aerosolized formulations of the present invention.10-15-2009
20100098642OPTIMISED FORMULATION OF TOBRAMYCIN FOR AEROSOLIZATION - The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium 04-22-2010
20090263335USE OF AEROSOLIZED CYCLOSPORINE FOR PREVENTION AND TREATMENT OF PULMONARY DISEASE - The present invention relates to methods and compositions for prevention of graft rejection in lung transplant recipients and for treatment of subjects with pulmonary disorders. Specifically, the methods and compositions of the invention provide a means for inhibiting immune response mediated inflammatory processes in the lungs. The method of the invention comprises the administration of aerosolized cyclosporine for prevention of acute and/or chronic refractory rejection in lung transplant patients. The invention further provides for the use of aerosolized cyclosporine to treat subjects having immunologically mediated inflammatory pulmonary disorders including, but not limited to, asthma, cystic fibrosis, idiopathic pulmonary fibrosis, chronic bronchitis and allergic rhinitis. The present invention, by enabling a method for the use of aerosolized cyclosporine for inhibiting pulmonary inflammation leading to prevention of graft rejection and treatment of pulmonary disorders, provides a safer and less toxic treatment than those methods that utilize systemic administration of cyclosporine.10-22-2009
20090263333Pharmaceutical compounds and compositions - The invention provides three polymorphic forms of crystalline levosalbutamol sulphate designated herein as Forms I, II and III. Crystalline levosalbutamol sulphate Form I is characterised by a powder XRD pattern with peaks at 10.8, 11.9, 13.0, 18.3, 28.5±0.2 degrees 2 theta. Crystalline levosalbutamol sulphate Form II is characterised by a powder XRD pattern with peaks at 8.7, 9.6, 15.2, 15.7, 19.1, 27.2, 30.7±0.2 degrees 2 theta. Crystalline levosalbutamol sulphate Form III is characterised by a powder XRD pattern with peaks at 5.5, 6.9, 7.3, 18.7±0.2 degrees 2 theta. Processes for making the new polymorphic forms and pharmaceutical compositions comprising them are also provided. A pharmaceutical composition comprises a therapeutically effective isomer of salbutamol or a salt, solvate, ester, derivative or polymorph thereof, a glucocorticoid and a pharmaceutically acceptable carrier or excipient and optionally one or more other therapeutic agents. Preferably the composition is an aerosol formulation comprising the drugs, a propellant and optionally one or more other ingredients, such as a surfactant, cosolvent, or bulking agent. Alternatively, DPI or inhalation suspensions may be used.10-22-2009
20090092557GRIFFITHSIN, GLYCOSYLATION-RESISTANT GRIFFITHSIN, AND RELATED CONJUGATES, COMPOSITIONS, NUCLEIC ACIDS, VECTORS, HOST CELLS, METHODS OF PRODUCTION AND METHODS OF USE - An isolated and purified nucleic acid molecule that encodes a polypeptide comprising at least eight contiguous amino acids of SEQ ID NO: 3, wherein the at least eight contiguous amino acids have anti-viral activity, as well as an isolated and purified nucleic acid molecule that encodes a polypeptide comprising at least eight contiguous amino acids of SEQ ID NO: 3, wherein the at least eight contiguous amino acids have anti-viral activity, and, when the at least eight contiguous amino acids comprise amino acids 1-121 of SEQ ID NO: 3, the at least eight contiguous amino acids have been rendered glycosylation-resistant, a vector comprising such an isolated and purified nucleic acid molecule, a host cell comprising the nucleic acid molecule, optionally in the form of a vector, a method of producing an anti-viral polypeptide or conjugate thereof, the anti-viral polypeptide itself, a conjugate or fusion protein comprising the anti-viral polypeptide, and compositions comprising an effective amount of the anti-viral polypeptide or conjugate or fusion protein thereof. Further provided are methods of inhibiting prophylactically or therapeutically a viral infection of a host.04-09-2009
20110200539Sprayable composition comprising extract of red vine leaves - Disclosed are sprayable compositions containing red vine leaf extract, which can be sprayed onto the skin using suitable spray devices.08-18-2011
20100124535Aerosol Dispersions of Particles with Active Pharmaceutical Ingredients - Aerosols containing a plurality of aqueous droplets, each droplet containing on average at least one essentially-neutral particle sized to fit within the droplet are provided. Aerosols wherein an active pharmaceutical ingredient is attached to, or otherwise incorporated in the essentially neutral particles are also provided. Methods for administering an active pharmaceutical ingredient to a subject in need thereof via inhalation of these aerosols, preferably via nebulizer, are also provided.05-20-2010
20090142279NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS - Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.06-04-2009
20110171141ADMINISTRATION OF DIHYDROERGOTAMINE MESYLATE PARTICLES USING A METERED DOSE INHALER - Disclosed are compositions of matter and related methods that provide a metered dose inhaler that includes a formulation having a dose that comprises a hydrofluoroalkane propellant and dihydroergotamine mesylate particles; wherein the dose includes between 0.1 mg to 4 mg of dihydroergotamine mesylate; wherein the dihydroergotamine mesylate particles have a cumulative drug substance particle size distribution with d10>0.5 micron volumetric median diameter and d90<5.0 micron volumetric median diameter.07-14-2011
20080206161QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF - The present invention relates to an emulsion steroid composition as a foamable vehicle in which the vehicle is stable or stabilized by the presence of at least one quiesence agent; therapeutical kit containing such composition; to methods of treatment using such composition; to methods of enhancing the stability of such composition.08-28-2008
20080206163Derivatives of pyrimido[6, 1-A]isoquinolin-4-one - Compounds of general formula (I) wherein each of R08-28-2008
20080206162Composition and Methods for Treating Alzheimer's Disease and Other Amyloidoses - A method of treating an amyloid disease in a patient or inhibiting the formation, deposition, accumulation, or persistence, of amyloid fibrils, amylin fibrils, or islet amyloid fibrils, and/or dissolving or disrupting pre-formed or pre-deposited amyloid fibrils in type II diabetes in a mammalian subject. In the method a therapeutically effective amount of plant matter form the genus 08-28-2008
20080206156Continuous spray scalp therapy and dispensing systems for same - The present invention relates to continuous spray medications involving the scalp, such as minoxidil, finesteride, copper peptides, DHT inhibitors and androgen receptor blockers, for example, in an amount sufficient to stimulate or maintain hair growth. The scalp medication is disposed within a pharmacologically acceptable carrier solution. In further embodiments, the spray scalp medication is dispensed within a product bag containing the medication in liquid form. The product bag is disposed within a container and includes a sheet of gas impervious material having a barrier layer therein. A gaseous propellant is also disposed within the container and is substantially separated from the medication. The valve assembly is selectively operated to produce a fine mist of said medication which is non-chilling, continuous and even.08-28-2008
20090274631RNAi-Mediated Inhibition of Histamine Receptor H1-Related Conditions - RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.11-05-2009
20090280069PROGUANIL TO TREAT SKIN/MUCOSAL DISEASES - Proguanil has been found to have rapid and effective killing activity against a variety of disease-causing micro-organisms. For example, when applied topically, proguanil is particularly effective against 11-12-2009
20090280066Methods and compounds for the treatment of mucus hypersecretion - A method of treating mucus hypersecretion, the causative factor in chronic obstructive pulmonary disease (COPD), asthma and other clinical conditions involving COPD, comprises administering a compound that inhibits exocytosis in mucus secreting cells or neurones that control or direct mucus secretion. Also described is a compound, for use in the treatment of hypersecretion of mucus, which inhibits mucus secretion by inhibiting mucus secretion by mucus secreting cells, and/or inhibiting neurotransmitter release from neuronal cells controlling or directing mucus secretion.11-12-2009
20090285764Azeotrope-Like Compositions of Tetrafluoropropene and Hydrofluorocarbons - Provided are azeotrope-like compositions comprising tetrafluoropropene and hydrofluorocarbons and uses thereof, including use in refrigerant compositions, refrigeration systems, blowing agent compositions, and aerosol propellants.11-19-2009
20090104125Stable liquid desoximethasone compositions with reduced oxidized impurity - The present invention relates to a stable liquid formulation comprising desoximetasone, isopropyl myristate, a C04-23-2009
20090297457Preparation Of Suspension Aerosol Formulations - The present invention provides processes for preparing suspension aerosol formulations, wherein the particles for inhalation are formed in situ during the process of manufacturing the formulation. In one aspect of the invention, a process for preparing a suspension aerosol formulation comprises the steps of: (a) dissolving one or more medicaments in one or more solvents to form a solution; and (b) mixing one or more propellants with the solution under conditions effective to precipitate, entirely or partially, at least one of the medicaments.12-03-2009
20090311195Compositions containing a solvated active agent suitable for dispensing as a compressed gas aerosol - A composition for solvating one or more active agents in an aqueous solution which is suitable for dispensing as a compressed gas aerosol composition is disclosed. The composition includes at least one surfactant, at least one active agent (such as a fragrance or an insecticide), and a compressed gas propellant. The at least one surfactant is preferably present in an amount from about 0.1 wt. % to about 3 wt. %. The at least one active agent is preferably present in an amount from about 0.1 wt. % to about 2 wt. %. The compressed gas propellant is preferably present in an amount from about 0.1 wt. % to about 1 wt. %. The total surfactant weight to active agent weight ratio for the composition is preferably about 1:3 to 5:1. The composition uses a reduced amount of surfactant and active agent thereby allowing for a more efficient active agent loading and a reduced stickiness or tackiness on surfaces contacted during use.12-17-2009
20090169486BIOMEDICAL FOAM ARTICLES - The present invention relates to biomedical foam articles for the wound sector which are formed by spraying a polymeric dispersion onto a wound. The polymeric dispersion being sprayed onto a wound surface forms a three-dimensional body which conforms to the spatial shape of the wound and which, as well as covering the wound surface, ensures a complete and accurately fitted packing of the wound in the depth dimension as well as the other dimensions. The biomedical foam articles of the present invention are particularly useful for treating chronic wounds.07-02-2009
20080241078COMPOSITIONS AND METHODS FOR TREATING HAIR LOSS USING C16-C20 AROMATIC TETRAHYDRO PROSTAGLANDINS - A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.10-02-2008
20080241077BENZOYLGUANIDINE SALT AND HYDRATES THEREOF - 4-[4-(2-pyrrolylcarbonyl)-1-piperazinyl]-3-trifluoromethylbenzoylguanidine hydrochloride and its hydrates, processes for preparing this benzoylguanidine salt and its hydrates, pharmaceutical compositions containing this benzoylguanidine salt and its hydrates, and its use in treating diseases, particularly those in which inhibition of the cellular Na10-02-2008
20080286209Compositions and Methods for Treatment of Neurological Symptoms Associated with Alcohol-Withdrawal and for Consulsive Seizure - Particular aspects of the present invention provide pharmaceutical compositions comprising isoprenoid-based compounds (e.g., farnesol and/or farnesol analogues or derivatives) or dehydroisoprenoid-based compounds, and novel methods for using same in treating (e.g., suppressing): alcohol withdrawal syndrome and associated neurological symptoms (e.g., depression, tremor, anxiety, autonomic hyperactivity (e.g., sweating, increased blood pressure, tachycardia), hallucinations, alcohol withdrawal seizures, delirium tremens (DT), and memory loss); or for treating in treating convulsive seizure (e.g., epileptic seizure, etc.). Particular pharmaceutical compositions and methods comprise the use of at least one compound selected from the group consisting of: (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol (all-trans farnesol); (2Z,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol (cis-farnesol); (E)-3,7,11-trimethyldodeca-1,6,10-trien-3-ol nerolidol); (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-amine (farnesylamine); (E)-3-(3,7-dimethylocta-2,6-dienyloxy)phenol (geranylresorcinol); (2E,6E)-,7,11-dimethyl-3-(trifluoromethyl)dodeca-2,6,10-trien-1-ol (trifluorofarnesol); and (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraen-1-ol (all-trans retinol). According to additional aspects, compounds that target and inhibit enzymes that degrade/metabolize/inactivate the disclosed compounds have utility to induce endogenous accumulation thereof to suppress/prevent, e.g., alcohol withdrawal seizures or convulsive seizures.11-20-2008
20080292561Pyrazolo-Pyrimidine Derivatives as Anti-Inflammatory Agents - A compound of formula (I):11-27-2008
20080292560SILICONE IN GLYCOL PHARMACEUTICAL AND COSMETIC COMPOSITIONS WITH ACCOMMODATING AGENT - A carrier, composition or foam formulation comprising; a silicone; about 25% to about 98% of a solvent selected from the group consisting of (1) a propylene glycol or derivative and (2) a polyethylene glycol (PEG) or derivative or mixtures thereof; 0% to about 48% of at least one secondary solvent; and an Accommodating Agent or Complex; and methods of treatment. A hygroscopic silicone in glycol containing composition includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of at least 0.9 and a therapeutic agent.11-27-2008
20100034753EDIBLE FOAM PRODUCT FOR THE TREATMENT OR PREVENTION OF OBESITY - The present invention relates to an edible foam product that can advantageously be used in the treatment or prevention of obesity. More particularly, the present invention provides an edible foam product of pourable or spoonable consistency having an overrun of at least 100%, said foam product containing at least 60 wt. % of water, from 1 to 7 wt. % of protein and from 1 to 20 wt. % of carbohydrates, and further being characterised by a high in-mouth stability as evidenced by a reduction in overrun of less than 35% under in-mouth shear conditions and a high gastric stability as evidenced by a t½>30 minutes, t 1/2 representing the time needed to achieve a reduction in overrun of 50% under gastric conditions. Another aspect of the invention relates to the use of an edible foam product in the treatment or prevention of overweight or obesity, said edible foam product having a pourable or spoonable consistency, an overrun of at least 100% and a high gastric stability as evidenced by t 1/2 >30 minutes. Yet another aspect of the invention concerns a pressurised container holding an edible liquid composition and a propellant, which liquid composition can be released from the container by activating a valve to produce an edible foam product having a pourable or spoonable consistency, an overrun of at least 100% and a high gastric stability as evidenced by t 1/2 >30 minutes.02-11-2010
20080286210NOVEL ANTIMICROBIAL PEPTIDES - This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against 11-20-2008
20090324511Compounds, Compositions and Methods - Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.12-31-2009
20090191136USE OF ACTIVE SUBSTANCE COMPLEXES OF PANTHENOL, GLYCEROL, CITRATE AND/OR BISABOLOL AGAINST POLLEN ALLERGIES - A cosmetic or dermatological preparation for combating or substantially preventing pollen allergies. The preparation comprises panthenol, glycerol and at least one of citrate and bisabolol and has at least one of (i) a pH of from about 4.6 to about 5.4, (ii) a mass ratio of panthenol to citrate of from about 25:1 to about 5:1, based on citrate anion, and (iii) a mass ratio of panthenol to bisabolol of from about 5:1 to about 1:1. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way.07-30-2009
20100143267EXTRACTS OF TETRASELMIS SP. - The present invention relates to extracts of 06-10-2010
20090304605Substituted Aminothiazole Prodrugs of Compounds with Anti-HCV Activity - The invention provides amino-substituted aminothiazole compounds of Formula I and Formula II12-10-2009
20120141385AZEOTROPE-LIKE COMPOSITIONS OF TETRAFLUOROPROPENE AND ALCOHOLS - A composition including an effective amount of trans-1,3,3,3-tetrafluoropropene component combined with an effective amount of an alcohol selected from the group of methanol, ethanol, propanol, isopropanol, tert-butanol, isobutanol, 2-ethyl hexanol and any combination thereof, where the composition has azeotropic properties.06-07-2012
20120141384ANTIBACTERIAL CONJUGATED BORONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF - A method of treating a disorder associated with a bacterial infection, consisting of administrating a pharmaceutical composition, comprising (a) a therapeutically effective amount of a conjugated boronic acid or a derivative thereof; and (b) a suitable pharmaceutical vehicle. The invention further relates to suitable pharmaceutical vehicles and pharmaceutical compositions for treating such disorders.06-07-2012
20090162297BUCCAL, POLAR AND NON-POLAR SPRAY CONTAINING ONDANSETRON - Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide ondansetron for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, ondansetron, and optional flavoring agent; formulation II: aqueous polar solvent, ondansetron, optionally flavoring agent, and propellant; formulation III: non-polar solvent, ondansetron, and optional flavoring agent; formulation IV: non-polar solvent, ondansetron, optional flavoring agent, and propellant; formulation V: a mixture of a polar solvent and a non-polar solvent, ondansetron, and optional flavoring agent; formulation VI: a mixture of a polar solvent and a non-polar solvent, ondansetron, optional flavoring agent, and propellant.06-25-2009
20090162298BUCCAL, POLAR AND NON-POLAR SPRAY CONTAINING SUMATRIPTAN - Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide sumatriptan for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, sumatriptan, and optional flavoring agent; formulation II: aqueous polar solvent, sumatriptan, optionally flavoring agent, and propellant; formulation III: non-polar solvent, sumatriptan, and optional flavoring agent; formulation IV: non-polar solvent, sumatriptan, optional flavoring agent, and propellant; formulation V: a mixture of a polar solvent and a non-polar solvent, sumatriptan, and optional flavoring agent; formulation VI: a mixture of a polar solvent and a non-polar solvent, sumatriptan, optional flavoring agent, and propellant.06-25-2009
20090162295SETTING POLYMERS BASED ON POLYESTER ACRYLATES - The present invention relates to cosmetic preparations which comprise at least one polymer A which comprises, in copolymerized form, at least one ester of (meth)acrylic acid, at least one olefinically unsaturated anionogenic or anionic compound, at least one polyester or polyether with at least two free-radically polymerizable, olefinically unsaturated double bonds, and if appropriate further olefinically unsaturated compounds.06-25-2009
20120070385Methods for Treating Cognitive/Attention Deficit Disorders Using Tetrahydroindolone Analogues and Derivatives - The present specification discloses tetrahydroindolone derivatives or analogues and methods for treating cognitive/attention deficit disorders using such tetrahydroindolone derivatives and analogues.03-22-2012
20090136431Stilbene Like Compounds as Novel HDAC Inhibitors - The present invention relates to novel stilbene like compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof. The present invention more particularly provides novel stilbene like compounds of the general formula (I). Also included is a method for treatment of cancer, psoriasis, proliferative conditions and conditions mediated by HDAC, in a mammal comprising administering an effective amount of a novel compound of formula (I) as described above.05-28-2009
20090175801CNS-TUMOR TREATMENT METHOD AND COMPOSITION - A method, aerosol composition, and aerosolizing device for treating a brain tumor in a subject are disclosed. The method includes intranasally administering to the subject, an amount of a telomerase inhibitor, such as an oligonucleotide telomerase inhibitor, effective to inhibit growth of the tumor in the subject.07-09-2009
20090175802TIOTROPIUM CONTAINING HFC SOLUTION FORMULATIONS - This invention relates to tiotropium containing stable pharmaceutical solution formulations suitable for aerosol administration. More particularly, this invention relates to tiotropium containing stable pharmaceutical solution formulations suitable for aerosol administration wherein either an inorganic acid or an organic acid is added to the aerosol solution formulation which contains a tiotropium salt, preferably tiotropium bromide in solution with an environmentally safe hydrofluorocarbon (HFC) as a propellant, together with an organic compound as a cosolvent. The acid provides stability against degradation or decomposition of the medicament resulting largely from interaction of the medicament with the cosolvent and/or water present in the solution formulation.07-09-2009
20090185982Approach to the treatment of compartment syndrome - The present invention relates to the use of an antisecretory protein or a derivative, homologue, and/or fragment thereof, having antisecretory activity, and/or a pharmaceutically active salt thereof, for the manufacture of a pharmaceutical composition and/or a medical food for the treatment and/or prevention of compartment syndrome. A compartment syndrome may be caused by or a cause of a variety of other conditions which are also encompassed by the present invention, such as viral and bacterial infections. Furthermore, the invention relates to a method for the treatment and/or prevention of compartment syndrome in a mammal in need thereof.07-23-2009
20090022669COMPOSITIONS FOR PROTEIN DELIVERY VIA THE PULMONARY ROUTE - Novel formulations comprising therapeutic agents, a surface tension-controlling agent, and a component that comprises both a humectant and a viscosity-controlling agent for use in thermal droplet ejecting devices are disclosed. The formulations are useful for maintaining controlled and reliable dosage of the therapeutic agent via pulmonary delivery.01-22-2009
20090053146Metronidazole-based dermatological foams and emulsions for the preparation thereof - Oil-in-water emulsions expandable into stable foams having diminished inhibitor of skin breathing and useful for the treatment of dermatological conditions/afflictions, e.g., rosacea, advantageously contain: 02-26-2009
20090053147Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules - Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated by cytokines.02-26-2009
20090324507RNAi-Mediated Inhibition of Spleen Tyrosine Kinase-Related Inflammatory Conditions - RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.12-31-2009
20090053145ANTI-VIRAL COMPOSITIONS AND METHODS OF USE IN CATTLE - Aspects of the present disclosure relate to therapeutic RNAi compositions and methods of use thereof for treating and/or preventing disease, disorder, and/or conditions—associated with bovine respiratory syncytial virus (BRSV) infections in cattle.02-26-2009
20090232745LICORICE LOLLIPOP THAT INHIBITS DENTAL CARIES FORMATION - This invention pertains to the discovery that certain extracts of licorice, particularly when formulated as a candy or lollipop or other means that provides an extended release (e.g., greater than about 4 minutes) to the oral cavity significantly inhibits the formation of dental caries in a human subject.09-17-2009
20090074675INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS - A compound of formula (I):03-19-2009
20090098063IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE - The invention provides the use of immune regulatory oligonucleotides (IRO) as antagonist of TLRs in the prevention and treatment of a disease caused by a pathogen, for example, a DNA or RNA virus.04-16-2009
20090098064METHOD OF TREATING PULMONARY EDEMA OR PULMONARY INFLAMMATION - The invention provides a method for preventing or treating pulmonary edema and/or pulmonary inflammation in a subject by the administration of at least one nucleotidase. The subject is preferably a human subject. The nucleotidase is preferably of a mammalian origin, such as a human origin. The NTPDase and NPP families of nucleotidases are particularly useful for the present invention. The method reduces the bioavailability of in situ signaling extracellular nucleotides, thereby disturbing the pathological pathways in ventilator-induced lung injury (VILI) and respiratory syncytial virus infection (RSV) and other disorders such as chronic obstructive pulmonary disorder. Local administration such as inhalation is a preferred route of administration.04-16-2009
20110229417Emollient Foams for Treatment of Seborrheic Dermatitis - Described herein are emulsions and compositions for the treatment of various dermatoses. The emulsions may be formulated as aerosol compositions. The aerosol propellant may be a hydrofluoroalkane propellant. Also described are methods of treating dermatoses, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive emulsion or aerosol composition. The dermatosis may be seborrheic dermatitis.09-22-2011
20080233053Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients - Disclosed is the use of a mist of a pharmaceutical composition for ophthalmic delivery of a protein or peptide active pharmaceutical ingredient, a related method of treatment and a device useful in implementing the use and method. Disclosed is also the use of a mist for ophthalmic delivery of a pharmaceutical composition including a highly irritating penetration enhancer and an ophthalmically acceptable carrier, a related method of treatment and a device useful in implementing the use and method. Disclosed is also a device for ophthalmic administration configured to direct a mist of a pharmaceutical composition to the eye only when the eye is open. Disclosed is also a self-sterilizing device for ophthalmic administration. Disclosed is also a device and a method for increasing the bioavailability of an ophthalmically administered API in a pharmaceutical composition.09-25-2008
20090162299Caffeine salt complexes and methods for using the same in the prevention or treatment of cancer - The present invention relates to pharmaceutical compositions containing a caffeine salt complex and a pharmaceutically acceptable carrier for use in methods for preventing or treating cancer or solar dermatitis. Methods for inducing apoptosis or inhibiting proliferation in a cancer cell or cell which as UVB-induced DNA damage using a caffeine salt complex or methylated xanthine are also provided.06-25-2009
20090208424COMPOSITIONS AND METHODS FOR DELIVERY OF SOLUTION TO THE SKIN - Compositions and methods for delivery of medicaments to human or animal skin, for example, the scalp, comprising the steps of transporting the medicaments in a volatile carrier solution to a position adjacent to the skin, and atomizing the preparation at said position onto the skin to thereby uniformly distribute the preparation over the scalp thereby improving absorption of the medicament through the skin08-20-2009
20090220436IN SITU POLYMERIZATION FOR SKIN TREATMENT - Cosmetics represent a world-wide multi-billion dollar industry. The present invention provides technology for polymerizing monomers on skin in situ to produce desired skin characteristics. For example, the inventive system may be used to reduce the signs of aging or to protect the treated skin from UV light. The polymerization of monomers on skin is typically initiated using a thermal or photoinitiatied free radical initiator. In certain embodiments, the monomers are fluorinated thereby producing a fluorinated polymer on the skin upon polymerization. The invention provides monomers, initiators, methods, and kits for use in treating skin with polymers.09-03-2009
20100003199Novel Protein Kinase C Therapy for the Treatment of Acute Lung Injury - The present invention provides novel formulations of a δPKC inhibitor. The δPKC inhibitor can be, for example, a peptide. The present invention also discloses a method of preventing acute pulmonary cell injury associated with trauma, ALI or ARDS and a method of inhibiting an inflammatory response in pulmonary cells by inhibiting the activity of δPKC. The invention also provides a method of treating a pulmonary disease with an aerosol formulation of a δPKC inhibitor to inhibit neutrophil activity.01-07-2010
20100178255Composition and method to treat otitis media and ventilator- associated pneumonia - A composition and method for prevention and treatment of otitis media and ventilator-associated pneumonia are described. The composition is made with GTase inhibitory polyphenol and polyhydric alcohol carrier. The composition is topical for intra-oral and otic use.07-15-2010
20090257959PESTICIDAL COMPOSITIONS - The present disclosure relates to pesticidal compositions and to methods for controlling pests such as insects and other arthropods. More particularly, the disclosure relates to a pesticidal compositions containing mineral oil and one or more additional components which, when used in combination, act synergistically to control insect and pest populations.10-15-2009
20100015063Benzodiazepine Derivatives and Pharmaceutical Compositions Containing Them - Benzodiazepine derivative of formula (I), and pharmaceutically acceptable salts thereof, are found to be active against RSV Formula (I) Wherein: —R01-21-2010
20100015062Method of treating pulmonary disease with interferons - A method of treating a pulmonary disease such as, for instance idiophathic pulmonary fibrosis (IPF), mixed connective tissue disease and asthma, comprising administering an aerosolized interferon such as interferon γ in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) alone or in combination with other therapeutic agents are provided.01-21-2010
20110229418Compositions and Methods of Treating and Preventing Lung Cancer - Compositions and methods for treating and preventing cancer, particularly lung cancer, are provided.09-22-2011
20090074676Inhibition of p38 MAPK For Treatment Of Obesity - The present invention is directed to the novel use of an inhibitor of CSBP/p38 Kinase for the treatment of obesity, and reducing weight loss in a mammal.03-19-2009
20100260688New Formulation and Use Thereof - Provided are liquid pharmaceutical formulations comprising nicotine in any form for administration essentially to the lungs being acidified and/or alkalized by buffering and/or pH regulation providing for a t10-14-2010
20100166672FOAM-FORMING COMPOSITION - The present invention relates to a novel foam-forming composition suitable for rectal administration of locally-acting pharmaceutically active ingredients, and the product adapted to administer said foam-forming composition. Also, the present invention relates to a method for its preparation. According to the present invention a foam-forming composition is provided which exhibits a high expansion ratio and at the same time conferring optimal appearance of the formed foam to allow sufficient contact time of the active to the target site in the intestine in order to obtain optimal local effect. The composition according to the present inventions provides superior properties for the treatment of rectal diseases.07-01-2010
20100021395CRYSTALLINE FORMS OF A BIPHENYL COMPOUND - The invention provides crystalline forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, and pharmaceutically acceptable solvates thereof. The crystalline form can be a freebase, or a salt such as a diphosphate, monosulfate or dioxalate salt. The invention also provides pharmaceutical compositions comprising these crystalline compounds or prepared using these compounds; processes and intermediates for preparing the crystalline compounds; and methods of using these compounds to treat a pulmonary disorder.01-28-2010
20100221194TOPICAL FOAM COMPOSITION - The present invention relates to a novel oil in water emulsion aerosol foam composition containing an active agent for the treatment of various chronic and acute skin conditions, particularly acne and psoriasis; and processes for preparing the emulsion aerosol foam compositions. In particular, the present invention relates to oil in water emulsion aerosol foam compositions containing a retinoid in the oil phase.09-02-2010
20110059027Biocidal aldehyde composition - A novel combination of OPA, a surfactant, and alcohol. The surfactant is preferably a dual chain quaternary ammonium compound consisting of a mixture of alkyl dimethyl-benzylammonium chlorides and alkyl dimethylethylbenzylammonium, that absorbs onto a surface and alters the free energy of that surface. The alcohol is preferably isopropyl alcohol. The OPA is the dialdehyde C03-10-2011
20100209357Localized Therapy of Lower Airways Inflammatory Disorders with Proinflammatory Cytokine Inhibitors - The present invention is drawn to methods and compositions for treating inflammatory disorders of the lower airways, comprising administering an effective amount of an agent, which modulates the expression and/or activity of a proinflammatory cytokine or fragment thereof, preferably in a human. The proinflammatory cytokine contemplated by the invention includes IL-1, IL-6, IL-8 and TNF-alpha. The present invention describes a kit comprising a delivery device and a pharmaceutical composition for administration of the agent. The pharmaceutical composition includes at least one proinflammatory cytokine inhibitor, optionally one or more additional active ingredients, and at least one pharmaceutically active carrier. The delivery device further comprises a nebulizer, an inhaler, a powder dispenser, an intrapulmonary aerosolizer and a sub-miniature aerosolizer.08-19-2010
20090041681Anti-inflammatory inhalation pharmaceutical composition - The present invention is directed to the discovery of the anti-inflammatory properties of basic amino salts of acetylcysteine when administered directly to the lungs and/or the nose.02-12-2009
20090041680Wax Foamable Vehicle and Pharmaceutical Compositions Thereof - Unique foamable vehicles or carriers comprising at least one wax, waxy substance, counterpart or derivative, a stabilizer, water, and a propellant are provided. In some embodiments, the wax is a liquid wax. In some embodiments, the wax includes a solid wax and a liquid wax. The compositions are substantially free of crystals. The components are selected to provide a composition that is substantially resistant to aging and to phase separation, and/or can substantially solubilize and or stabilize active ingredients. Pharmaceutical and cosmetic compositions with potentially enhanced skin delivery and their uses are also provided.02-12-2009
20090041679HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES TO H5N1 INFLUENZA A VIRUS - A panel of IgG02-12-2009
20090041678Metronidazole-based dermatological foams and emulsions for the preparation thereof - Oil-in-water emulsions expandable into stable foams having diminished inhibitor of skin breathing and useful for the treatment of dermatological conditions/afflictions, e.g., rosacea, advantageously contain: 02-12-2009
20120034172PHARMACEUTICAL FORMULATION COMPRISING A PHOSPHODIESTERASE INHIBITOR - Pharmaceutical formulations to be administered by pressurized metered dose inhalers (pMDIs), comprising a compound of general formula (I) may be used for the treatment and/or prevention of inflammatory or obstructive airway diseases.02-09-2012
20080311052Isis Pharmaceuticals, Inc. - Disclosed herein are compounds, compositions and methods for modulating the expression of STAT 6 in a cell, tissue, or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of STAT 6, airway hyperresponsiveness, and/or pulmonary inflammation.12-18-2008
20090110646Product for Treating the Skin and Mucous Membranes, and Relative Method of Preparation - A method for preparing a product for treating the skin and mucous membranes comprises the steps of making available a suitable quantity of trichloracetic acid, making available a suitable quantity of hydrogen peroxide, making a first mixture of the trichloracetic acid and the hydrogen peroxide, making available a determinate quantity of the basic compound able to achieve a buffer effect of the trichloracetic acid comprised in the first mixture, and adding the basic compound.04-30-2009
20100297033Megaribavirin alone or combination of other antiviral, antioxidant and a perflubron emulsion for treatment of viral disease - The present invention is a novel method using a MegaRibavirin aerosol or a MegaRibavirin combination of therapeutics for the treatment of viral disease particularly the pandemic influenza strains “swine” 2009 H1N1 and H5N1. This invention utilizes Ribavirin in an aerosol Mega Dose (61-161 mg/ml) alone or combined with or without other antivirals, a perfluorocarbon emulsion and anti-inflammatory/anti-oxidants. Where applicable, the perfluorocarbon emulsion may dissolve these agents enabling a depot effect and possible protracted delivery. In addition perfluorocarbon emulsions have the possible added benefit of oxygen carrying capacity and alveolar nitric oxide sequestration, which may reduce peroxynitrite formation and decrease Influenza severity.11-25-2010
20100297035Thiazole Amides, Imidazole Amides and Related Analogues - Thiazole amides, imidazole amides and related analogues of the Formula: are provided, in which variables are as described herein. Such compounds may be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) and other disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).11-25-2010
20100297034OSMOLYTE-CONTAINING PREPARATION FOR USE IN CASE OF DRY MUCOUS MEMBRANES - The present invention relates to osmolyte-containing preparations for the local treatment of dry mucous membranes. It describes the use of osmolytes for the production of a medicament, medical product or cosmetic product for the prevention, therapy and/or care of dry mucous membranes. The present invention relates to topical compositions based on osmolytes to which sodium chloride and/or moisturizers can optionally be added. The group of osmolytes proposed by the invention embraces various low-molecular substances, in particular ectoine, homoectoine, hydroxyectoine, di-myo-inositol phosphate (DIP), cyclic 2,3-diphosphoglycerate (cDPG), 1,1-di-glycerol phosphate (DGP), β-mannosylglycerate (Firoin), β-mannosylglyceramide (Firoin-A), di-mannosyl di-inositol phosphate (DMIP), glucosylglycerol and/or a derivative, e.g. an acid, salt or ester, of these compounds.11-25-2010
20100303736ANTI-IL-9 ANTIBODY FORMULATIONS AND USES THEREOF - The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to an IL-9 polypeptide, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to an IL-9 polypeptide, which formulations are substantially free of surfactants, sugars, sugar alcohols, amino acids other than histidine (preferably with pKa values of less than 5 and above 7), and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating a disease or disorder associated with or characterized by aberrant expression and/or activity of an IL-9 polypeptide, a disease or disorder associated with or characterized by aberrant expression and/or activity of the IL-9R or one or more subunits thereof, an autoimmune disease, an inflammatory disease, a proliferative disease, or an infection (preferably, a respiratory infection), or one or more symptoms thereof, utilizing the liquid formulations of the present invention.12-02-2010
20090214444POLY AROMATIC SODIUM CHANNEL BLOCKERS - Polyaromatic sodium channel blockers represented by the formula:08-27-2009
20090214443METHOD FOR RETARDING SYSTEMIC DELIVERY RATE FOR EASILY ABSORBABLE ACTIVE AGENTS - Drugs such as hormones, which are easily absorbable through the stratum corneum into the vascular network, are administered to the skin of a patient in an absorption retarding matrix material, thereby retarding the rate at which the drug penetrates into and through the skin.08-27-2009
20110008268PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY - The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.01-13-2011
20110008269Compositions and Methods Which Modulate G-Protein Signaling for the Treatment of Inflammatory Disorders such as Asthma and Allergic Conjunctivitis - Compositions and methods for the treatment of asthma and inflammatory ocular disorders are disclosed.01-13-2011
20090068117STAY-ON SELENIUM FOAM - Provided, among other things, is a delivery module for a non-greasy, non-irritating selenium sulfide composition comprising: (A) an aerosol delivery device; (B) within the aerosol delivery device, the selenium sulfide composition comprising an effective amount of selenium sulfide that is 1% or more by weight of the composition, and a frothing agent, wherein the selenium sulfide composition has a viscosity low enough to support aerosol delivery and the selenium sulfide composition is effective to form a foam upon propellant-driven aerosol delivery; and (C) within the aerosol delivery device, a propellant.03-12-2009
20090035225RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA - RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions associated with elevated intraocular pressure (IOP), including glaucoma and ocular hypertension.02-05-2009
20110038807COMPOSITIONS AND METHODS FOR TREATING BIPOLAR DISORDER - The present invention is directed to a method for treating bipolar disorder, childhood-onset bipolar disorder, and associated symptoms. The method includes administering to a subject in need of such treatment a dose of ketamine sufficient to alleviate symptoms associated with bipolar disorder and childhood-onset bipolar disorder.02-17-2011
20110020244PHARMACEUTICAL COMPOSITIONS - The present invention relates to pharmaceutical compositions and in particular to suspension aerosol pharmaceutical compositions, processes to obtain them and their use in inhalation therapy.01-27-2011
20110212035EMOLLIENT FOAMS FOR TREATMENT OF DERMATOSES - Described herein are emulsions and compositions for the treatment of various dermatoses. The emulsions may be formulated as aerosol compositions. The aerosol propellant may be a hydrofluoroalkane propellant. Also described are methods of treating dermatoses, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive emulsion or aerosol composition. The dermatosis may be atopic dermatitis, allergic contact dermatitis, or radiation dermatitis.09-01-2011
20090324506Sprayable skin protectant formulation and method of use - The present disclosure is directed to a skin protectant formulation that is designed to be sprayed onto human skin for the purpose of protecting the skin. In particular, an exemplary formulation of the present disclosure contains at least a carrier, a structurant and a skin protectant agent. An exemplary formulation contains a carrier comprising at least water, a structurant comprising at least a laponite clay, and a skin protectant agent comprising petrolatum. Typically, the skin protectant formulation will comprise at least about 30 wt. % of a skin protectant agent. A continuous spray dispenser may be used to apply the skin protectant formulation to reduce the need for rubbing as the treated area can be covered by a mist of the skin protectant formulation requiring no need to rub for application or small droplets that do not require extensive time for rubbing in.12-31-2009
20100008866CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES - Cis-cyclohexyl substituted pyrimidinone derivatives are provided, of the Formula:01-14-2010
20100008867METHOD OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS - The present invention relates to methods, uses, and compositions comprising the caspase inhibitor (R)-N-((2S,3S)-2-(fluoromethyl)-2-hydroxy-5-oxo-tetrahydrofuran-3-yl)-5-isopropyl-3-(isoquinolin-1-yl)-4,5-dihydroisoxazole-5-carboxamide, or a pharmaceutically acceptable salt thereof.01-14-2010
20100055046COMPOSITION AND METHOD FOR TREATING COLDS - Viral upper respiratory tract infections, upper respiratory infections, and common colds can be effectively treated by the administration of a combination of a nasal steroid and a nasal antihistamine. By the administration of the combination of a nasal steroid and a nasal antihistamine with the onset of cold symptoms, the histamine cascade and the inflammatory response are impeded or eliminated, reducing the severity, duration, or frequency of the onset of cold symptoms. The combination of a nasal steroid and a nasal antihistamine may be, for example, a physical mixture of the steroid and antihistamine, or it may effectively be a combination wherein the patient is administered one component (either the steroid or the antihistamine) followed by the other, without physical mixing beforehand.03-04-2010
20100055048ACUTE TREATMENT OF HEADACHE WITH PHENOTHIAZINE ANTIPSYCHOTICS - Methods of treating headache with antipsychotics are provided. A kit for treating headache is also provided, comprising an antipsychotic and a device for rapid delivery of the antipsychotic.03-04-2010
20100055047Methods for treating bronchial premalignancy and lung cancer - The present invention is directed to methods for treating bronchial premalignancy and/or lung cancer in a subject comprising administering to the subject an aerosolized pharmaceutical composition comprising a therapeutically effective amount of 5-azacytidine and a pharmaceutically acceptable carrier. The present invention is also directed to methods for decreasing the likelihood of occurrence of bronchial premalignancy and/or lung cancer in a subject comprising administering to the subject an aerosolized pharmaceutical composition comprising a prophylactically effective amount of 5-azacytidine and a pharmaceutically acceptable carrier. The present invention is also directed to pharmaceutical compositions for treating bronchial premalignancy and/or lung cancer in a subject comprising a therapeutically effective amount of 5-azacytidine and a pharmaceutically acceptable carrier. The present invention is also directed to pharmaceutical compositions for decreasing the likelihood of occurrence of bronchial premalignancy and/or lung cancer in a subject comprising a prophylactically effective amount of 5-azacytidine and a pharmaceutically acceptable carrier.03-04-2010
20110081301PHARMACEUTICAL AEROSOL FORMULATIONS OF FORMOTEROL AND BECLOMETASONE DIPROPIONATE - Pharmaceutical formulations comprising beclometasone dipropionate and a salt of formoterol exhibit improved stability and are useful in pressurised metered dose inhalers (pMDIs).04-07-2011
20110076238COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE PROCESSES - The invention relates to the use of anticholinergics for preparing a pharmaceutical composition for the prevention and treatment of proliferative processes.03-31-2011
20120148504COMPLEX OF GARCINOL, CYCLODEXTRIN AND METHOD THEREOF - The present disclosure discloses a pharmaceutical molecule of Garcinol chemically complexed with cyclodextrins and the use of the complexed molecule in prevention and management of cardiac dysfunction induced by chemotherapy, drugs and/or other insults to the heart caused by lifestyle and disease conditions. The disclosure also relates to a method of extraction and purification of high yield of 95-99% pure Garcinol from 06-14-2012
20110150784COMBINATION THERAPY FOR COPD - Aerosol formulations comprising glycopyrronium chloride in combination with formoterol may be administered by means of a pressurized metered dose inhaler (pMDI) for the prevention or treatment of chronic obstructive pulmonary disease. The formulation further comprises a HFA propellant, a co-solvent, and an amount of inorganic acid sufficient to stabilize both the glycopyrronium chloride and the formoterol components. Optionally, the formulation may further comprise beclometasone dipropionate.06-23-2011
20120171127VOC-FREE COMPRESSED GAS AEROSOL COMPOSITION - Certain surfactants suitable for use alone to dissolve a water-insoluble component in compositions is described for providing VOC-free compressed gas aerosol compositions. The compositions include water-insoluble component(s), a surfactant and water. The water-insoluble component(s) can be active agent(s), such as fragrance(s) and/or an insecticide(s). The surfactant is present as a single surfactant which, in the absence of a solvent, dissolves or disperses the water-insoluble component(s) and provides a homogenous blend in water which provides a stable compressed gas emulsion. The surfactant is an anionic surfactant or a nonionic surfactant, in particular nonionic alkylpolyglycosides; nonionic cocoglucoside; nonionic alkylene oxide extended chain alkylpolyglycosides; anionic sodium lauryl ether sulfate (SLES), nonionic C07-05-2012
20090022670NOVEL COMPOUNDS - Disclosed are imidazo[1,2-a]pyridin-2-ylmethyl substituted piperidine derivatives of formula (I)01-22-2009
20080247964SUBSTITUTED AZASPIRO DERIVATIVES - Substituted azaspiro derivatives of the Formula:10-09-2008
20080247963Quinuclidine Compounds Having Quaternary Ammonium Group, Its Preparation Method and Use as Blocking Agents of Acetylcholine - The invention relates to the quinuclidine compounds of formula I having quaternary ammonium group, its preparation, and the pharmaceutical composition comprising an effective amount of the compound of formula I. The compound and the composition are used to prevent and treat the diseases by blocking acetylcholine receptor.10-09-2008
20110150785Light Inhibitors For Asthma, Lung and Airway Inflammation, Respiratory, Interstitial, Pulmonary and Fibrotic Disease Treatment - Methods of treating inflammatory conditions, disease and disorders are provided. Method include, for example, contacting or administering a sufficient amount of a LIGHT inhibitor to a subject to treat the inflammatory condition, disease or disorder.06-23-2011
20110150782COMBINATION THERAPY FOR COPD - Aerosol formulations comprising glycopyrronium bromide in combination with formoterol are useful for the prevention or treatment of chronic obstructive pulmonary disease. The formulation further comprises a HFA propellant, a co-solvent, and an amount of inorganic acid sufficient to stabilize both the glycopyrronium bromide and the formoterol components. Optionally the formulation may further comprise beclometasone dipropionate.06-23-2011
20090324510DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES - The present invention relates to novel drug combinations which, besides one or more, preferably on compound of the general formula (1), wherein remainder n, A, R1, R2, and R3 can have the meanings given in the claims and in the description comprise at least one further active ingredient 2 and method for the production thereof and the use thereof as drugs.12-31-2009
20090324508Broad Spectrum and Skin Friendly Disinfecting Composition - The present invention discloses a composition for use in a foam dispenser comprising: 0.1-5% (w/w) hydrogen peroxide, 21-55% (w/w) of a C2-C6 alcohol, and 0.01-2% (w/w) of a foam booster. The foam booster is capable of providing a stable foam when dispensing a composition consisting of 36% (w/w) ethanol and 0.2% (w/w) of the foam booster from a foam dispenser. The composition provided as a foam is suitable for disinfecting skin and/or mucous membranes.12-31-2009
20090317338FOAMABLE IODINE COMPOSITIONS - The present invention is related to a foamable composition of matter comprising iodine, water, a foam adjuvant, a surface-active agent and a gelling agent. This foamable composition, which may be provided in a propellant free foaming device, or alternatively may further comprise a propellant, evolves into foam, which is effective in the topical treatment and prevention of various skin disorders.12-24-2009
20090180969PHARMACEUTICAL FORMULATION COMPRISING AN ANTICHOLINERGIC DRUG - Pharmaceutical formulations suitable to be administered by pressurised metered dose inhalers (pMDIs) comprising a salt of 3-[[[(3-fluorophenyl)[(3,4,5-trifluoro phenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane are effective for the prevention and/or treatment of an obstructive airways disease.07-16-2009
20080279789Combination Of Dehydroepiandrosterone Or Dehydroepiandrosterone-Sulfate With An Anticholinergic Bronchodilator For Treatment Of Asthma Or Chronic Obstructive Pulmonary Disease - A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising an anticholinergic bronchodilator for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases.11-13-2008
20080279790AZEOTROPE-LIKE COMPOSITIONS OF PENTAFLUOROPROPANE AND CHLOROPROPANE - This invention provides azeotrope-like compositions of 1,1,1,3,3-pentafluoropropane and 2-chloropropane that are environmentally desirable for use as refrigerants, aerosol propellants, metered dose inhalers, blowing agents for polymer foam, heat transfer media, and gaseous dielectrics.11-13-2008
20080279787Hard Surface Disinfecting Compositions Comprising Poorly Aqueous Soluble Quaternary Ammonium Compounds - Disinfecting compositions based on one or more poorly aqueous soluble quaternary ammonium compounds which exhibit reduced corrosion tendencies, one or more nonionic surfactants, optionally one or more further constituents particularly those which enhance the appearance of the compositions, wherein the compositions are largely aqueous in nature and includes little or no organic solvents. The compositions may be formulated as aerosol compositions, or may be provided as non-pressurized liquid compositions. The disinfecting compositions provide excellent efficacy against 11-13-2008
20080279786Method for Extending Lifespan Delaying the Onset of Age-Related Disease - A method and composition for extending the lifespan of an individual and delaying the onset of age-related disease is provided. The method includes the administration of an effective dose of oxaloacetate, wherein the oxaloacetate acts to mimic the cellular conditions obtained under caloric restriction to provide similar benefits. The invention further includes methods and compositions for reducing the incidence or treatment of cancer. Compositions and methods for reducing body fat by administering an effective amount of oxaloacetate are likewise provided. Compositions for DNA repair in UV damaged cells is provided are also provided. Similarly, a method for treating a hang-over comprising administering an effective amount of oxaloacetate is disclosed.11-13-2008
20080279785Novel synthetic agonists of toll-like receptors containing CG dinucleotide modifications - The invention relates to the therapeutic use of oligonucleotides as immune modulatory agents in immunotherapy applications. More particularly, the invention provides immune modulatory oligonucleotide compositions for use in methods for generating an immune response or for treating a patient in need of immune modulation. The immune modulatory oligonucleotides of the invention preferably comprise novel pyrimidines and purines.11-13-2008
20110256070PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ADMINISTERING THE SAME - The present invention provides pharmaceutical compositions and methods for dispensing the same using an aerosol whereby the composition takes the form of foam. Additionally, the present invention provides a barrier system including a concentrate separated from a non-chlorine aerosol propellant wherein the concentrate includes a non-aqueous solvent, an emulsifying agent, a thickening agent, at least one medicament and optionally an aqueous solvent.10-20-2011
20080267888Heterocyclic Derivatives - The present invention relates to novel heterocyclic derivatives of the general formula (I), their pharmaceutically acceptable salts and compositions, their analogs, their tautomeric forms, and their stereoisomers. The present invention more particularly provides novel compounds of the general formula (I).10-30-2008
20110081302PROCESS FOR THE OBTENTION OF PURIFIED HEPTAFLUOROPROPANE - Process for the obtention of HFC-227ea having a reduced content of organic impurities, comprising at least subjecting a crude HPC-227ea to two distillation steps at different pressures.04-07-2011
20100329998NOVEL HETEROCYCLES - Described are novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. These compounds are useful in the treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; atherosclerosis; cancer; cachexia; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; ARDS; psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; asthma; COPD; bone resorption diseases; multiple sclerosis; sepsis; septic shock; toxic shock syndrome and fever. More particularly these compounds are useful as PDE4 inhibitors and are useful for treating PDE4 mediated diseases.12-30-2010
20100329997USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION - The present invention relates to the use of creatine compounds such as, for example, creatine, creatine phosphate or analogs of creatine, such as creatine-pyruvate, creatine-ascorbate, cyclocreatine, 3 guanidinopropionic acid, guanidinoacetate, homocyclocreatine, guanidino benzoates as energy generating systems and antioxidants for preservation of skin against adverse aging effects and damage secondary to insults such as harmful sun radiations, stress and fatigue. The creatine compounds which can be used in the present method include (1) creatine, creatine phosphate and analogs of these compounds which can act as substrates or substrate analogs for creatine kinase; (2) molecules that mimic the biological activity of creatine (3) molecules that modulate the creatine kinase system.12-30-2010
20100329995COMPOSITIONS CONTAINING LACTOFERRIN, AND METHODS OF USING SAME TO PROMOTE GROWTH OF SKIN CELLS - The present invention relates, generally, to compositions including lactoferrin, and to compositions including both lactoferrin and lysozyme. The present invention also includes topical formulations containing the compositions, methods of making the formulations, methods of using the formulations to treat various skin disorders/conditions, to treat wounds, and to methods of producing artificial skin using the composition, and methods of treating burns using the formulation, optionally in conjunction with the application of artificial skin.12-30-2010
20110135582COMBINATION OF MEDICAMENTS FOR THE TREATMENT OF RESPIRATORY DISEASES - A pharmaceutical composition comprising: 06-09-2011
20110135581Methods and Compositions for Reducing Lung Inflammation in an Animal - The present invention provides methods for reducing, attenuating, diminishing, preventing or inhibiting pulmonary inflammation in an animal by orally administering a plasma fraction to said animal prior to or following exposure or challenge of the animal to an endotoxin.06-09-2011
20110135580Novel Medicament Combinations for the Treatment of Respiratory Diseases - The present invention relates to new medicament combinations which contain in addition to one or more, preferably one, compound of general formula 106-09-2011
20110052506Stable Aerosol Topical Foams Comprising a Hypochlorite Salt - Described herein are compositions useful in the treatment of atopic dermatitis and other skin conditions, which compositions exhibit enhanced stability. The compositions contain a hypochlorite salt, useful for its antimicrobial properties, and are non-irritating when applied to the skin. The compositions also provide enhanced moisturizing properties. The compositions can be formulated into a topical aerosol foam with inert, non-flammable propellants, such as hydrofluoroalkanes, and may be used in cosmetics or pharmaceuticals.03-03-2011
20100322871Co-polymer Stabilizers For Hydryfluoroalkane Dispersions - The use of biodegradable and biocompatible lactide-based nonionic amphiphiles to stabilize a model drug (salbutamol base) dispersion in hydrofluoroalkane (HFA) propellant is disclosed. The results have industrial applicability to the development of HFA-based dispersion pressurized metered-dose inhaler formulations.12-23-2010
20090311196PHARMACEUTICAL AEROSOL COMPOSITION - Compositions which contain an active ingredient, a propellant containing a hydrofluoroalkane (HFA), a co-solvent, and a low-volatility component are useful for administering the active ingredient via an aerosol.12-17-2009
20110097280Intracorporeal Medicaments for Photodynamic Treatment of Disease - New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations including liquid, semisolid, solid or aerosol delivery vehicles.04-28-2011
20110097279STABLE NON-ALCOHOLIC FOAMABLE PHARMACEUTICAL EMULSION COMPOSITIONS WITH AN UNCTUOUS EMOLLIENT AND THEIR USES - A stable non-alcoholic foamable pharmaceutical emulsion composition includes an unctuous emollient, at a concentration of about 0.5% to about 49% by weight; at least one multi-active agent; at a concentration of about 0.5% to about 15% by weight; water; an effective amount of an active pharmaceutical agent having a degree of solubility in the emulsion composition; and at least one liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition; wherein the unctuous emollient comprises a petrolatum alone or in combination with other unctuous agents; wherein the multi active agent is selected from the group consisting of (a) two or more complex emulgators wherein there is a difference of about 4 or more units between the HLB values of two of the emulgators or there is a significant difference in the chemical nature or structure of two of the emulgators; (b) a surfactant and a foam adjuvant or co surfactant, wherein the surfactant has a HLB close to the required HLB of the oil phase; (c) a surfactant and a liquid wax, wherein the surfactant has a HLB close to the required HLB of the oil phase; (d) a surfactant and a polymeric agent other than starch or a modified starch ester, wherein the surfactant has a HLB close to the required HLB of the oil phase; (e) a polymeric agent and a foam adjuvant or co surfactant, which can cooperate to stabilize the emulsion; (f) a single surfactant without a long polymeric side chain that is composed of a mixture of esters having a HLB close to the required HLB of the oil phase; combinations of any of the above, and wherein the composition is substantially flowable is stored in an pressurized container and upon release expands to form a breakable foam.04-28-2011
20100166676RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS - RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.07-01-2010
20100166673AEROSOLIZED FLUOROQUINOLONES AND USES THEREOF - Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.07-01-2010
20100166674TRANSDERMAL DELIVERY RATE CONTROL USING AMORPHOUS PHARMACEUTICAL COMPOSITIONS - A pharmaceutical composition for transdermal delivery comprising 07-01-2010
20100068156AMPHOLYTIC COPOLYMER BASED ON QUATERNIZED NITROGEN-CONTAINING MONOMERS - The present invention relates to an ampholytic copolymer based on quaternized nitrogen-containing monomers which has a molar excess of cationogenic/cationic groups compared to anionogenic/anionic groups, to cosmetic or pharmaceutical compositions which comprise at least one such ampholytic copolymer, and to further uses of these copolymers.03-18-2010
20110189106INTRANASAL COMPOSITIONS, DOSAGE FORMS AND METHODS OF TREATMENT - Various embodiments of the present invention provide for compositions, dosage forms and methods useful in treating, relieving or prophylactically treating of one or more symptom of an allergic and/or inflammatory condition.08-04-2011
20110189105GRIFFITHSIN, GLYCOSYLATION-RESISTANT GRIFFITHSIN, AND RELATED CONJUGATES, COMPOSITIONS, NUCLEIC ACIDS, VECTORS, HOST CELLS, METHODS OF PRODUCTION AND METHODS OF USE - An isolated and purified nucleic acid molecule that encodes a polypeptide comprising at least eight contiguous amino acids of SEQ ID NO: 3, wherein the at least eight contiguous amino acids have anti-viral activity, as well as an isolated and purified nucleic acid molecule that encodes a polypeptide comprising at least eight contiguous amino acids of SEQ ID NO: 3, wherein the at least eight contiguous amino acids have anti-viral activity, and, when the at least eight contiguous amino acids comprise amino acids 1-121 of SEQ ID NO: 3, the at least eight contiguous amino acids have been rendered glycosylation-resistant, a vector comprising such an isolated and purified nucleic acid molecule, a host cell comprising the nucleic acid molecule, optionally in the form of a vector, a method of producing an anti-viral polypeptide or conjugate thereof, the anti-viral polypeptide itself, a conjugate or fusion protein comprising the anti-viral polypeptide, and compositions comprising an effective amount of the anti-viral polypeptide or conjugate or fusion protein thereof. Further provided are methods of inhibiting prophylactically or therapeutically a viral infection of a host.08-04-2011
20110189104SURFACTANT PROTEIN D FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH LUNG INJURY - Surfactant protein D (SP-D) is a 43-kDa member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. Described herein are methods and compositions for the treatment of disorders associated with lung injury, including methods and compositions for the treatment of bronchopulmonary disorder (BPD) using recombinant human surfactant protein D and surfactant formulations.08-04-2011
20100028268Compositions and Methods For Treating Infectious Bronchitis - A prophylactic treatment for infectious bronchitis as well as a treatment of infectious bronchitis. The methods comprise the step of administering to a bird, an amount of a composition having a first ingredient obtainable from turmeric; a second ingredient obtainable from green tea; an third ingredient obtainable from ginger; and an acceptable carrier. Compositions in accordance with the invention may be employed for the purpose of reducing the incidence of contracting infectious bronchitis or reducing the transmissivity of infectious bronchitis.02-04-2010
20100028266Composition and methods for treating allergic response - The invention generally relates to compositions and methods for treating and/or preventing an allergic response with reduced rebound hyperemia, comprising highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume, and histamine antagonists. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.02-04-2010
20100021394HIGH PENETRATION PRODRUG COMPOSITIONS OF 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINES AND 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINE-RELATED COMPOUNDS - The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of 1H-imidazo[4,5-c]quinolin-4-amines and 1H-imidazo[4,5-c]quinolin-4-amine-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.01-28-2010
20090246148Medicinal aerosols and methods of delivery thereof - The replacement of chlorofluorohydrocarbon propellants in medical aerosols is of the utmost importance to the pharmaceutical industry. A number of formulations have been investigated.10-01-2009
20090148389INDUCTION OF MUCOSAL TOLERANCE TO ANTIGENS - Induction of tolerance to antigens by mucosal, preferably oral, delivery of the antigen in combination with an immunomodulating compound producing micro-organism is disclosed. More specifically, Foxp306-11-2009
20090130026PHARMACEUTICAL SOLUTION FORMULATIONS FOR PRESSURISED METERED DOSE INHALERS - The invention relates to the prevention and/or treatment of a severe broncho-pulmonary disease by administering a solution formulation from a pressurized metered dose inhaler capable of providing therapeutical doses of two or more active drug substances to the lung, wherein all the active drug substances are fully dissolved in the formulation as well as the two or more active drug substances are delivered with substantially the same particle size distribution.05-21-2009
20090004120Antimicrobial Compositions - Provided are personal care products and compositions that comprise at least one preservative compound selected from the group consisting of phenoxyethanol, 2-phenyl ethanol, phenoxypropanol, 3-phenylpropanol and benzylalcohol, in a total concentration of 0.1 to 1% (w/w); and at least one preservative enhancer compound selected from the group consisting of 4-methylbenzaldehyde, heliotropine, vanilline, 4-hydroxybenzaldehye, 3-hydroxybenzaldehyde, 4-methoxybenzaldehyde, 3-methoxybenzaldehyde, 2,4-dihydroxybenzaldehyde, 3-hydroxy-4-methoxybenzaldehyde, 3,5-dihydroxybenzaldehyde, and 4-hydroxy-2-methoxybenzaldehyde, in a total concentration of 0.05 to 0.5% (w/w), in a cosmetically acceptable base. The composition does not contain certain classic bactericidal, fungicidal, sporicidal or preservative compounds. Further provided are methods of forming such compositions and products and the use of preservatives and preservative enhancers in such compositions and products.01-01-2009
20100034754METHOD FOR MAKING INSECT REPELLENT COMPOSITION - Dihydronepetalactone, a minor natural constituent of the essential oil of catmints (02-11-2010
20090232743Foamable Microemulsion Compositions for Topical Administration - Described are ethanol-free foamable microemulsions for topical application, and method of making them. The propellants used in the compositions may be environmentally-friendly hydrofluoroalkanes. The foam compositions may also comprise one or more of a variety of active ingredients, including anti-inflammatory agents, anesthetics, and keratolytic agents.09-17-2009
20080260653Transdermal Delivery Systems and Transdermal Chelation Preparations - The invention provides topical chelating preparations and formulations. The invention provides methods of transepithelial delivery of a topical chelating preparation to a human or other animal by topical application to the skin of a human or animal of a topical chelating preparation. In one aspect, a preparation or formulation of the invention comprises a combination comprising of 2-3, dimercaptopropane-1-sulfonate (DMPS) or glutathione, and methionine, in a stabilizing base.10-23-2008
20080206160Short bio-active peptides for cellular and immunological modulation - Peptides having four to fourteen residues are disclosed that possess biological activity. These peptides constitute short fragments of the peptide HB-107 (SEQ ID NO:1), which itself is a fragment of the antimicrobial protein cecropin B, and exhibit cell stimulatory, migratory and anti-inflammatory properties. As keratinocytes are especially sensitive to these effects, the disclosed peptides comprise a useful agent for the medical treatment of injury to the skin, such as from diabetic ulcers. The peptides also are effective in preventing and reversing skin surface damage resulting from various environmental insults. Importantly, the therapeutic effects of the peptides manifest at concentrations equal to or greater than those of peptide HB-107, and thus represent a less expensive, more versatile means for developing effective therapies. Methods for the production and use of these peptides are also disclosed.08-28-2008
20090202446MICROEMULSION COMPOSITION FOR AIR FRESHENER - The present invention relates to air freshener devices of water-based liquid compositions, preferably clear liquids, that provide an improved diffusion of the composition and allow the use of fragrance materials with a wide range of characteristics, namely a wide range of clogP values. The compositions are clear microemulsions particularly adapted for use in automatic air fresheners and comprise at least 40% w/w of an aqueous phase, preferably water, an active oil in an amount of between 0.01 and 5% w/w, an oil-solubilizing system which is formed of a surfactant mixture of ionic and non-ionic surfactants, a solubilizing-aid ingredient in an amount of up to 5% w/w, and a propellant system in an amount of up to 40% w/w, wherein the perfume oil to total surfactant mixture is present at a weight ratio of between 0.2 and 4.5.08-13-2009
20110117030Aerosolized Fosfomycin/Aminoglycoside Combination for the Treatment of Bacterial Respiratory Infections - A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having mass median aerodynamic diameter predominantly between 1 to 5μ, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler.05-19-2011
20090130027COMPOSITIONS AND METHODS FOR TREATING PURPURA - Embodiments of the present invention are directed to compositions and methods for the treatment of purpura. Preferred compositions comprise an α adrenergic receptor agonist selected from selective α05-21-2009
20080267887Pyrrolo-Pyridine, Pyrrolo-Pyrimidine and Related Heterocyclic Compounds - Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds analogues of the formula:10-30-2008
20100129294NATTOKINASE FOR DEGRADING AND REDUCING AMYLOID FIBRILS ASSOICATED WITH ALZHEIMER'S DISEASE, PRION DISEASES AND OTHER AMYLOIDOSES - A method of dissolving or disrupting pre-formed or pre-deposited amyloid fibrils and/or inhibiting amyloid formation, deposition, accumulation, or persistence in Alzheimer's disease, prion diseases and/or other amyloidoses in a mammalian subject is disclosed. In the method a therapeutically effective amount of nattokinase is administered.05-27-2010
20110305646FATTY ACID MONOGLYCERIDE COMPOSITIONS - The present invention relates to a method of treating a fungal condition caused by 12-15-2011
20110305645CRYSTAL FORM OF GLYCOPYRRONIUM CHLORIDE - A new crystal form of threo glycopyrronium chloride is useful in pharmaceutical applications.12-15-2011
20110305644 Wool Care Composition - The present invention relates to a wool care composition comprising pyrethroid insecticide, a copolymer and a solvent wherein the said copolymer binds with the solvent and pyrethroid insecticide. This composition can be an improved aerosol spray formulation for treating of pure or blended woollen clothing and textile, fur and feather lined garments and other keratinous items for protection or insect proofing from various types of insect pests both clothes moths and carpet beetles during their storage, transport and use. Wool care aerosol solution can be sprayed with pressurized container having either a propellant as ready-to-use aerosol or manually operated sprayers. The aerosol spray composition may also contain fragrance and solvent. The other components in the composition are at least one copolymer/emulsifier and/or dispersant.12-15-2011
20110305643High Oil-Content Emollient Aerosol Foam Compositions - Described herein are high oil-content emulsions and compositions for the treatment of inflammatory skin disorders. The emulsions may be formulated as aerosol compositions. The aerosol propellant may be a hydrofluoroalkane propellant. The emulsions or compositions may comprise active agents, such as corticosteroids. Also described are methods of treating inflammatory skin disorders, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive emulsion or aerosol composition.12-15-2011
20080311050Method for Producing Shape Memory Effects in Hair in Connection with Hydrophobic Active Ingredients - A method for achieving a retrievable hair restyling is described. Here a composition is applied to the hair, said composition containing at least one first active ingredient or active ingredient complex which can provide a shape memory effect by itself or in combination with other substances after being applied to the hair and after the performance of the treatment of the hair according to the invention. The composition additionally contains at least one second active ingredient, namely a hydrophobic substance with a water solubility of ≦5 percent by weight at 20° C. The hair is arranged into a given (permanent) shape and said permanent shape is then fixed by inducing a chemical or physical modification of the applied active ingredients, wherein after a wanted or unwanted deformation of the shape memory, the original shape memory can be restored by means of a physical stimulation. In addition to the permanent hairstyle, a second (temporary) shape can be impressed. A method is also described for restoring a previously programmed permanent hairstyle that was temporarily transformed into a temporary shape or that was otherwise deformed.12-18-2008
20090169485Gene therapy and pharmaceutical composition for prevention and treatment of lung cancer - Disclosed herein is a gene therapeutic agent and pharmaceutical composition for the prevention and treatment of lung cancer. For aerosol delivery, chemically synthesized polyester amine is used as a carrier in the gene therapeutic agent. The polyester amine/Akt1 siRNA complex is found to be effectively delivered to the lungs of K-ras null mice through a nose-only inhalation system and to significantly suppress lung cancer progression as denoted by gene delivery efficiency and inhibition of Akt-related signals and cell cycle. Thus, the aerosol delivery of polyester amine-mediated Akt1 siRNA is provided as an effective model for noninvasive gene therapy.07-02-2009
20100226863HOMEOPATHIC MEDICAMENT USEFUL FOR IMMUNOMODULATION - Homeopathic immunomodulator medicament, auxiliary in the treatment of the immunolog Formula: formed by 1000 ml of the hydro-alcoholic solution, and variables of 09-09-2010
20100055045METHOD AND SYSTEM FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED ANTICHOLINERGIC ADMINISTRATIONS - A method is provided for improving lung function in COPD by administering a muscarinic antagonist with a high efficiency nebulizer.03-04-2010
20090257958PESTICIDAL COMPOSITIONS - The present disclosure relates to pesticidal compositions and to methods for controlling pests such as insects and other arthropods. More particularly, the disclosure relates to a pesticidal compositions containing mineral oil and one or more additional components which, when used in combination, act synergistically to control insect and pest populations.10-15-2009
20110110869STABLE HYDROALCOHOLIC COMPOSITIONS - Disclosed is a composition including a lower alcohol and water in a weight ratio of about 35:65 to 100:0, between at least 0.5% and 8.0% by weight thickener system comprised of at least two emulsifiers, each emulsifier present in at least 0.05% by weight and wherein each emulsifier is comprised of at least one hydrophobic group and at least one hydrophilic group. The composition is useful as a presurgical scrub replacement, a lotion or other hand preparation.05-12-2011
20090028801Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections - A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by 01-29-2009
20080286211Using mucin glycoproteins in combination with therapeutic agents to treat epithelial lesions and disorders of impaired mucin function - The present invention features methods of treating a patient having an epithelial lesion or disorder of impaired mucin function. The present invention further features methods of treating pain associated with epithelial lesions and disorders of impaired mucin function. Epithelial lesions and disorders of impaired mucin function can be treated using a pharmaceutical composition containing mucin glycoproteins in combination with therapeutic agents, e.g., trefoil polypeptides.11-20-2008
20100196286INHALATION DELIVERY METHODS AND DEVICES - Methods, devices and kits for treating sleep disorders, anxiety disorders, and developmental disorders, and/or for inducing an arousable state of sedation in a subject, are described. For example, inhalation methods, devices and kits for treating insomnia, anxiety and/or ADHD using one or more α2-adrenergic agonists such as dexmedetomidine or clonidine are described.08-05-2010
20090087389DEHYDROEPIANDROSTERONE SULFATE DIHYDRATE INHALATION COMPOSITIONS AND METHODS - The invention relates to inhalation compositions derived from dehydroepiandrosterone sulfate. The compositions of the invention involve liquid nebulizer formulations prepared from dehydroepiandrosterone sulfate dihydrate. The compositions of the invention comprise water and chloride ion. The liquid nebulizer formulations can be used to treat patients suffering from asthma or COPD.04-02-2009
20080317679FOAMABLE COMPOSITIONS AND KITS COMPRISING ONE OR MORE OF A CHANNEL AGENT, A CHOLINERGIC AGENT, A NITRIC OXIDE DONOR, AND RELATED AGENTS AND THEIR USES - The present invention relates to a foamable therapeutic composition comprising: (a) a therapeutically effective concentration of at least one active agent selected from the group consisting of a channel agent, a cholinergic agent, and a nitric oxide donor; and (b) a foamable carrier comprising: 12-25-2008
20090324509INSECTICIDAL COMPOSITION - A pesticidal composition which comprises cymene and either a pyrethrin insecticide or an insect growth regulator. In particular the composition is formulated as an aerosol for killing or controlling pests and in particular flying pests.12-31-2009
20090142280Protective skin care peptides - The disclosed invention provides tetrapeptides with the amino acid sequence proline-glutamine-glutamate-X (P-Q-E-X), where X can be either lysine (K) or isoleucine (I). These tetrapeptides inhibit ultraviolet light (UV)-induced expression of the pro-inflammatory cytokine interleukin-6 (IL-6) by skin epithelial cells and fibroblasts. Furthermore, the tetrapeptides repress the upregulation of matrix metalloproteinase-1 (MMP-1) by skin fibroblasts induced by either direct exposure to UV rays or treatment with media conditioned by UV-treated keratinocytes. The small size and bio-activity of the tetrapeptides render them suitable for use in therapies directed to inflammatory skin disorders and as active ingredients in skin care products.06-04-2009
20110318277TACROLIMUS COMPOSITIONS FOR AEROSOL ADMINISTRATION - The present disclosure relates generally to highly concentrated macrolide solutions for aerosol administration, and related methods of producing and administering the same. In one aspect, provided herein is a receptacle containing a highly concentrated solution of a macrolide compound such as tacrolimus, where the solution exhibits long-term stability in a pMDI canister and achieves high respirable fractions when actuated, among, other features. In yet another aspect, provided is a composition suitable for aerosol administration comprising tacrolimus dissolved in an ethanol-liquified propellant mixture, characterized by a tacrolimus concentration of greater than 0.15 weight percent (w/w) and comprising no more than about 10 weight percent (w/w) ethanol.12-29-2011
20110318278FOAMABLE SUSPENSION GEL - The present subject matter provides foamable suspension gels that foam after release from a container. The foamable suspension gels contain at least one pharmaceutically active agent that is sparingly soluble to insoluble in water, a second pharmaceutically active agent, and optionally a third active agent.12-29-2011
20110318276Aerosol composition with enhanced dispersion effects - A stable, high VOC, single phase, non-aqueous liquid aerosol composition having enhanced dispersion based on reduced particle size and increased evaporation rate to result in improved active ingredient dispersion, slower settling in air and less residue on surfaces. The composition includes at least one hydrocarbon propellant, at least one active ingredient and a solvent blend. The solvent blend includes at least one low volatility solvent and at least one high volatility solvent wherein each has a defined vapor pressure and Hansen solubility parameter. The composition upon dispersion as a spray has an aerosol particle size of less than 30 microns.12-29-2011
20120207685Non-ozone depleting medicinal formulations with low greenhouse effect - Pharmaceutical pressurized metered dose inhalers are disclosed having a composition free of CFCs and totally or partially free of HFAs, thus allowing the manufacture of medicinal aerosols without damaging the atmospheric ozone layer and with low or negligible greenhouse effect.08-16-2012
20080260655SUBSTANTIALLY NON-AQUEOUS FOAMABLE PETROLATUM BASED PHARMACEUTICAL AND COSMETIC COMPOSITIONS AND THEIR USES - The present invention relates to stable substantially non-aqueous, non-alcoholic, non-silicone, foamable carrier compositions comprising petrolatum or mixtures thereof, at least one foam agent, at least one propellant, and with and without the addition of an active agent. The formulations may contain a solvent substantially miscible therein. The present invention further provides a method of treating, alleviating or preventing a disorder of mammalian subject in need thereof, comprising administering the above-mentioned compositions to an afflicted target site of said mammalian subject.10-23-2008
20100008868SUSTAINED REMISSION OF ATOPIC DERMATITIS - It has been found that the combination of an antihistamine with a corticosteroid is more effective in the treatment of atopic dermatitis than either one used separately. The synergistic effect in some cases results in the disappearance of the atopic dermatitis lesion within one to five days with little or no relapse. Compositions and the methods of utilizing these preparations are disclosed.01-14-2010
20090169487Essential Oil Diffusion - A method for treating and/or alleviating at least one symptom associated with impaired airway clearance of mucous, impaired oxygen intake, and/or infection in a patient suffering from a respiratory ailment and/or restrictive lung disease includes administering to the patient an effective amount of an essential oil composition including at least one essential oil selected from 07-02-2009
20120058058COMPOUNDS DERIVED FROM MUSCODOR FUNGI - The present invention relates to novel compounds and compositions and the use of them for the control of fungal and bacterial pathogens, insect pests, acari, nematodes and other invertebrate pests including, but not limited to post-harvest and soil diseases, building mold remediation, and seed and grain sanitation.03-08-2012
20120014882SKIN CARE COMPOSITIONS - Anhydrous sunscreen compositions that include a volatile solvent, an organic UV-filter dissolved in the volatile solvent, a water-insoluble, low-volatility, C01-19-2012
20120058056TREATMENT OF CUTANEOUS HEMANGIOMA - This invention concerns a method of treating hemangiomas with a beta blocker by applying the beta blocker onto the hemangiomas directly. The invention also concerns a combination therapy by using a beta blocker along with a corticosteroid or an alpha adrenergic receptor agonist for the treatment of hemangiomas.03-08-2012
20120064014AZEOTROPE-LIKE COMPOSITIONS COMPRISING 1-CHLORO-3,3,3-TRIFLUOROPROPENE - An azeotrope-like mixture consisting essentially of chlorotrifluoropropene and at least one component selected from the group consisting of a C03-15-2012
20090081132Water-borne aerosol composition - A water-borne aerosol composition containing an oil soluble insecticidal component (A), a hydrophobic organic solvent (B), water (C), a non-ionic surfactant (D) and a propellant (E), wherein the oil soluble component (A) is 4-methoxymethyl-2,3,5,6-tetrafluorobenzyl 3-(2-cyano-1-propenyl)-2,2-dimethylcyclopropanecarboxylate and wherein the non-ionic surfactant (D) has a HLB in the range of 4.1 to 7.0, shows an excellent insecticidal activity and is useful.03-26-2009
20110104079FOAMABLE ALCOHOLIC COMPOSITION - A foamable composition is provided that includes at least 40 weight percent alcohol, based upon the total weight of the alcoholic composition; a foaming surfactant selected from the group consisting of anionic, cationic, and zwitterionic fluorosurfactants, and combinations thereof; and a polymeric or oligomeric foam stabiliser selected from the group consisting of polyquaterniums, quaternized copolymers of vinylpyrrolidone and dimethylamino methacrylate, hydrophobically modified quaternized copolymers of vinylpyrrolidone & dimethylaminopropyl methacrylamide, and mixtures thereof. Methods of forming a stabilised foam and of reducing dripping from a dispenser are also provided.05-05-2011
20100092403BUCCAL, POLAR AND NON-POLAR SPRAY CONTAINING ZOLPIDEM - Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide zolpidem for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, zolpidem, and optional flavoring agent; formulation II: aqueous polar solvent, zolpidem, optionally flavoring agent, and propellant; formulation III: non-polar solvent, zolpidem, and optional flavoring agent; formulation IV: non-polar solvent, zolpidem, optional flavoring agent, and propellant; formulation V: a mixture of a polar solvent and a non-polar solvent, zolpidem, and optional flavoring agent; formulation VI: a mixture of a polar solvent and a non-polar solvent, zolpidem, optional flavoring agent, and propellant.04-15-2010
20100092402TREATMENT OF RESPIRATORY DISEASE - The invention relates to the use of amidino compounds in the manufacture and formulation of medicaments for the treatment of respiratory diseases.04-15-2010
20100092401IMMUNE RESPONSE MODIFIER FORMULATIONS - The present invention provides a pharmaceutical foam formulation. Generally, the formulation includes a therapeutically effective amount of imiquimod and a fatty acid.04-15-2010
20100166675Pharmaceutical Composition for the Treatment of Type 1-Diabetes - A composition for the prevention or treatment of type I diabetes in a subject, said composition comprising a GABAergic and incretin exemplified by GABA and GLP-1/Ex4. These are optionally provided together in a single composition to promote beta-cell regeneration prevent beta-cell apoptosis and control autoimmunity for the prevention and treatment of T1D in mammals.07-01-2010
20120164081NON-HAZARDOUS FOAMING ANT SPRAY BASED ON NATURAL OILS, CARBOXYLATE SALTS AND OPTIONAL SYNERGISTS - A foaming insecticidal ant spray is described that minimally comprises an essential oil, an emulsifier, a carboxylate salt and water, which has maximum mortality on ants. A method for killing and controlling ants is described wherein the composition is foamed directly onto the ants whereby the ants become entangled within the foam, increase their contact time with the compositions, and perish.06-28-2012
20100247449FOAMABLE COMPOSITION ESSENTIALLY FREE OF PHARMACEUTICALLY ACTIVE INGREDIENTS FOR THE TREATMENT OF HUMAN SKIN - The present invention related to the use of a pharmaceutical composition which is essentially free of pharmaceutically active ingredients for the treatment of human skin, especially in the treatment of rosacea, acne, atopic dermatitis, contact dermatitis, perioral dermatitis, psoriasis or neurodermitis, as well as for prophylactic and/or cosmetic purposes.09-30-2010
20120128598Topical Pharmaceutical Foam Composition - A stable topical alcohol-free aerosol foam containing one or more keratolytic agents is provided. The foam-forming formulation is an oil-in-water emulsion which contains one or more hydrofluoroalkane (HFA) propellants and one or more keratolytic agents. The keratolytic agent may be present in either phase of the emulsion or dispersed in the emulsion. The oil phase may consist at least in part of the HFA propellant. The foam is stable on the skin for at least 5 minutes at body temperature and disappears into the skin upon rubbing or after prolonged standing. The formulations may not contain additional co-solvents or non-HFA co-propellants. The formulations demonstrate reduced intensity of the odor and/or color associated with the keratolytic agent(s) as compared to conventional formulations containing keratolytic agents.05-24-2012
20100209358Method of Making Particles For Use In A Pharmaceutical Composition - The invention relates to a method for making composite active particles for use in a pharmaceutical composition for pulmonary administration, the method comprising a milling step in which particles of active material are milled in the presence of particles of an additive material which is suitable for the promotion of the dispersal of the composite active particles upon actuation of an inhaler. The invention also relates to compositions for inhalation prepared by the method.08-19-2010
20110182830INHALATION DRUG PRODUCTS, SYSTEMS AND USES - Various embodiments of the present invention provide drug products, inhalation systems and methods of treating respiratory diseases. Several embodiments provide an inhalation system including a pressurized metered dose inhaler and a chamber. The chamber may be an anti-static chamber with a chamber volume of about 145 milliliters (ml) to about 200 ml.07-28-2011
20110182831SYSTEMS AND METHODS USED IN CONJUNCTION WITH NICOTINE VACCINES FOR EFFECTING CESSATION OF TOBACCO USE - The invention relates generally to a system and method for treating conditions responsive to nicotine therapy. More specifically, the invention relates to administering a nicotine vaccine or nicotine antibody along with pulmonary administration of a nicotine containing formulation to affect smoking cessation.07-28-2011
20120134935USE OF MOMETASONE FUROATE FOR TREATING AIRWAY PASSAGE AND LUNG DISEASE - The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.05-31-2012
20120134934GLYCINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF - Alkaloid aminoester derivatives according to formula (I) and (VI) act as muscarinic receptor antagonists.05-31-2012
20100172845COMPOSITIONS AND METHODS FOR TREATING MYCOBACTERIAL INFECTIONS - Disclosed are compositions and improved methods for effective treatment of Mycobacterial infections in susceptible animals. Also disclosed are regimens for preventing, reducing, or ameliorating the emergence of symptoms of 07-08-2010
20120171126NOVEL [3,2-c] HETEROARYL STEROIDS AS GLUCOCORTICOID RECEPTOR AGONISTS COMPOSITIONS AND USES THEREOF - The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, or isomers of said compounds), having the general structure: Formula (I) wherein L, R07-05-2012
20100047186Peptides and Their Use - The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino acids in the amino sequence of said peptide are the same, for use as antibacterial agents.02-25-2010
20100047188MODULATION OF TOLL-LIKE RECEPTOR 8 EXPRESSION BY ANTISENSE OLIGONUCLEOTIDES - Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR8. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR8. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR8 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating TLR8 expression and for prevention or treatment of diseases wherein modulation of TLR8 expression would be beneficial are provided.02-25-2010
20100047187METHODS OF TREATING PARKINSON'S DISEASE USING HALOGENATED VOLATILE COMPOUNDS - The present invention provides methods of using halogenated volatile compounds, e.g., halogenated ether, for treating a neurological disorder, e.g., Parkinson's disease.02-25-2010
20100047185ACTVIE SUBSTANCE COMBINATION - The present invention refers to a combination of at least 2 UV-absorbing active substances (A) and (B), wherein the UV-absorbing active substance (A) is at least one heptaazaphenalene compound of the general formula (I), which is defined in the description and the UV-ab-sorbing active substance (B) is at least one compound which has its ab-sorption maximum λ02-25-2010
20100291002COMBINATION COMPRISING PYRROLIDONE-5-CARBOXYLIC ACID AND AT LEAST ONE COMPOUND FROM CITRULLINE, ARGININE AND ASPARAGINE, AND USE THEREOF IN THE TREATMENT OF ATOPIC DERMATITIS - Combination comprising pyrrolidone-5-carboxylic acid and at least one compound from citrulline, arginine and asparagine, and use thereof in the treatment of atopic dermatitis The present invention relates to a composition comprising, in a physiologically acceptable carrier, pyrrolidone-5-carboxylic acid and at least one compound from citrulline, arginine and asparagine, in racemic or isomer form, and salts thereof, for the preparation of a medicament for use in the treatment and/or prevention of atopic dermatitis.11-18-2010
20100272654LEVALBUTEROL SALT - Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.10-28-2010
20120082626USE OF R-BAMBUTEROL AS INHALED MEDICAMENT AND COMBINATION THERAPIES FOR TREATMENT OF RESPIRATORY DISORDERS - The present invention concerns with a new use of R-Bambuterol or Bambuterol as inhaled medicament for treatment of asthma, COPD and other respiratory disorders, and a new use of R-bambuterol or bambuterol and corticosteroids or other therapeutically active medicament as combined inhaled therapies. The invention also related to a new use of R-bambuterol with reduced drug tollerance and risk of exerbation of asthma associated with bambuterol in treatment of respritroy discorders.04-05-2012
20120263655COMBINATION OF MEDICAMENTS FOR THE TREATMENT OF RESPIRATORY DISEASES - A pharmaceutical composition comprising: 10-18-2012
20090016971Aqueous fluid photoprotective compositions comprising tertiary-amide-terminated polyamide polymers - Topically applicable, fluid anti-sun/sunscreen compositions useful for protecting the skin and/or the hair against the damaging effects of ultraviolet radiation, contain: 01-15-2009
20090016970CONTINUOUS SPRAY SCALP THERAPY AND DISPENSING SYSTEMS FOR SAME - A spray delivery system in combination with a scalp medication is provided which includes a portable container having a gas imperious container wall, a pressure source disposed within the container, and a selectively operable valve assembly affixed to the container. The scalp medication is in liquid form and is disposed within the container. The scalp medication comprises a hair growth stimulation or hair growth maintenance active ingredient in an amount sufficient to stimulate or maintain hair growth disposed within a pharmacologically acceptable carrier solution. The valve assembly of the system produces a 1 mL spray of said scalp medication within about 5 seconds following a single operation of said valve assembly. A method of treating alopecia using a continuous spray employing such a system is also provided. Both bag-on-valve (bag-in-can) and metered dose packages are disclosed.01-15-2009
20090016968COMPOSITION AND METHOD FOR PREVENTION AND TREATMENT OF TYPE I DIABETES - A composition for the prevention or treatment of type I diabetes in a subject, said composition comprising a fusion protein selected from the group consisting of GLP-1/IgG or variant or fragment thereof and an Ex4/IgG or variant or fragment thereof and an autoimmune suppressor for silencing an autoimmune response against islet beta cells.01-15-2009
20090162300BUCCAL, POLAR AND NON-POLAR SPRAY CONTAINING ALPRAZOLAM - Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide alprazolam for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, alprazolam, and optional flavoring agent; formulation II: aqueous polar solvent, alprazolam, optionally flavoring agent, and propellant; formulation III: non-polar solvent, alprazolam, and optional flavoring agent; formulation IV: non-polar solvent, alprazolam, optional flavoring agent, and propellant; formulation V: a mixture of a polar solvent and a non-polar solvent, alprazolam, and optional flavoring agent; formulation VI: a mixture of a polar solvent and a non-polar solvent, alprazolam, optional flavoring agent, and propellant.06-25-2009
20080299049Inhalation nebulizer - The aerosol generator of an inhalation therapy device according to a preferred embodiment of the invention continuously produces an aerosol at a generation rate of about 0.2 ml/min to about 1.5 ml/min, preferably 0.4 ml/min to about 1.2 ml/min and the mixing chamber has a volume of about 60 ml to about 150 ml, preferably about 80 ml to about 120 ml, and even more preferably about 90 to about 110 ml. While the patient inhales through the inhalation therapy device, the generated aerosol is inhaled by the patient. While the patient exhales into the inhalation therapy device, the generated aerosol is collected in the mixing chamber. Due to the specific size of the mixing chamber, the continuously generated aerosol can accumulate therein without losses even when the exhalation phase is longer than the inhalation phase like in the case of emphysema.12-04-2008
20080299048MIXED DRUG AEROSOL COMPOSITIONS - The present invention pertains to aerosols which comprise a first compound which is physiologically active and a second compound which is different from the first compound. Such aerosols may be produced “on demand” and can be used to control drug release, to improve vaporizability, or to reduce, modify or eliminate undesirable taste associated with a drug aerosol. The present invention also pertains to methods for producing such aerosols.12-04-2008
20100202978FOAMABLE BENZOYL PEROXIDE COMPOSITIONS FOR TOPICAL ADMINISTRATION - Described herein are benzoyl peroxide compositions useful in the treatment of acne and other skin conditions, which exhibit enhanced stability, even under accelerated conditions. The compositions also exhibit reduced color formation, reduced irritation, and enhanced moisturizing properties. They can be formulated into a topical aerosol foam with inert, non-flammable propellants, such as hydrofluoroalkanes, and may be used in cosmetics or pharmaceuticals. Additionally, methods of formulating these compositions are described.08-12-2010
20110002856Compositions Containing Volatile Solvents - According to the present invention there is provided a use of a cyclic oligosaccharide for delaying the release of a volatile solvent from a composition, preferably a cosmetic composition, which comprises at least 50% volatile solvent.01-06-2011
20110002855PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES - Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues of the formula (I): are provided, as are methods for their preparation and use. Such compounds may generally be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and therapeutic methods are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).01-06-2011
20110002854Use of Francisella Tularensis For Prevention and Treatment of Allergic Airway Disorders - A pharmaceutical composition for treating or preventing a Th01-06-2011
20120269740USE OF BENZYLOXY-ETHYLAMINE DERIVATIVES AS A PRESERVATIVE, PRESERVATION METHOD, AND COMPOSITIONS - The invention relates to the use of a compound of formula (I), or salts thereof, as a preserving agent, in particular in a cosmetic, dermatological or pharmaceutical composition:10-25-2012
20110236321Aerosol Foams Comprising Clindamycin Phosphate - Described herein are emulsions and compositions for the treatment of acne vulgaris. The emulsions may be formulated as aerosol compositions. The aerosol propellant may be a hydrofluoroalkane propellant. The emulsions or compositions may comprise clindamycin phosphate and a buffer salt, and may exhibit decreased rates of clindamycin phosphate hydrolysis. Also described are methods of treating acne vulgaris, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive emulsion or aerosol composition.09-29-2011
20100239507SURFACE MODIFIED AEROSOL PARTICLES, A METHOD AND APPARATUS FOR PRODUCTION THEREOF AND POWDERS AND DISPERSIONS CONTAINING SAID PARTICLES - A method and apparatus for multicomponent surface modified aerosol particle production suitable for, for instance, therapeutic, cosmetic or diagnostic use in which an aerosol containing an active agent is introduced in an aerosol reactor together with a surface agent or surface agent source and/or precursor and wherein the surface agent and/or surface agent precursor is volatilizable. The surface agent vapor saturation ratio is elevated so to cause it to nucleate from the gas phase. Reactor conditions are maintaining such that the active agent remains in the condensed phase and provides a surface for the surface agent to deposit on the active agent containing aerosol particle thus producing surface modified aerosol particles. The method can be used for batch or continuous production. Particles made according to the method and powders and dispersions containing the particles are also described.09-23-2010
20100233099DEVICE FOR INTRANASAL ADMINISTRATION - Disclosed herein are devices and processes for preparing a vial for an intranasal administration of a medicament where the vial comprises reduced oxygen content.09-16-2010
20100202979Compositions and methods for treatment of pulmonary diseases and conditions - The invention provides compositions and methods for treating pulmonary diseases and conditions. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists having a binding affinity of 300 fold or greater for α-2 over α-1 adrenergic receptors. The compositions preferably comprise brimonidine and/or dexmedetomidine.08-12-2010
20120087873Urea Foam - Provided, among other things, is a delivery module for a non-greasy, water-based urea composition comprising: an aerosol delivery device; within the aerosol delivery device, the urea composition comprising 20% or more urea by weight, non-greasy lipophilic component(s), and a frothing agent, the urea composition having a viscosity low enough to support aerosol delivery, and the urea composition effective to form a foam upon propellant-driven aerosol delivery; and within the aerosol delivery device, a propellant.04-12-2012
20110293535COMPOSITION FOR BUCCAL ABSORPTION OF NICOTINE FOR THE PURPOSE OF SMOKING CESSATION - Composition intended for buccal absorption of nicotine into the system circulation and distribution to the central nervous system for the purpose of smoking cessation or nicotine substitution in conditions adverse for smoking according to the invention contains nicotine solution in form of a base and/or its salt with organic acid in concentration 0.01 to 8.00% by weight and substances with mucolytic effect. Single application dosage contains 0.05 to 3.00 mg of nicotine.12-01-2011
20120328531STABLE LIQUID DESOXIMETHASONE COMPOSITIONS WITH REDUCED OXIDIZED IMPURITY - The present invention relates to a stable liquid formulation comprising desoximetasone, isopropyl myristate, a C12-27-2012
20100215589Carbamate Stereoisomer - The compound of formula (I)08-26-2010
20100215588THERAPEUTIC DELIVERY OF INHIBITORY NUCLEIC ACID MOLECULES TO THE RESPIRATORY SYSTEM - The present invention relates to methods of treating respiratory disorders of all types, including pulmonary disorders, by delivering inhibitory nucleic acid molecules directly to the respiratory system. siRNAs or other nucleic acids are delivered to the lung/respiratory system for the treatment of disease.08-26-2010
20130011342SURFACTANT-FREE, WATER-FREE FORMABLE COMPOSITION AND BREAKABLE FOAMS AND THEIR USES - A substantially surface active agent-free and foam adjuvant-free composition which includes a hydrophobic solvent, a wax and a propellant. A substantially surface active agent-free and foam adjuvant-free composition, further comprising, a tetracycline antibiotic, or one or More other active agents. A method of treatment, using a substantially surface active agent-free and substantially foam adjuvant-free composition.01-10-2013
20080253970Stable Pharmaceutical Drug Products - Various aspects of the present invention provide for methods of manufacturing a pharmaceutical drug product, which include storing a container at a temperature greater than ambient conditions for at least about seven days and conducting release testing on the container after storing. Products manufactured by this method have a more consistent fine particle size distribution (FSD) and fine particle fraction (FPF) at ambient conditions and at accelerated stability conditions over the life of the drug product. Advantageously, such products may more reliably and regularly pass testing requirements as required for an approved drug product by regulatory authorities such as the United States Food and Drug Administration (USFDA).10-16-2008
20080247965PRESSURISED METERED DOSE INHALERS (MDI) - The invention relates to pressurized metered dose inhalers (MDIs) in which all or part of the internal surface is lined with an inert organic coating and which contain a formulation which comprises TA 2005.10-09-2008
20080247962Pharmaceutical Compositions Comprising Higher Primary Aliphatic Alcohols and Hmg Coa Reductase Inhibitor and Process of Preparation Thereof - A novel pharmaceutical composition comprising a mixture of higher primary aliphatic alcohols from (24) to (39) carbon atoms; at least one another component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds, and HMG CoA reductase inhibitor, its salts, analogs or derivatives thereof, preferably statins, optionally with pharmaceutically acceptable excipients, and process of preparation of such composition is provided. Also provided are method of treatment and use of such composition for reducing abnormal lipid parameters associated with hyperlipidemia.10-09-2008
20090162296Approach to treat intraocular hypertension - The present invention relates to the use of antisecretory factors, such as antisecretory proteins, homologues, derivatives and/or fragments thereof having antisecretory activity, for the manufacture of a pharmaceutical composition for use in the treatment and/or prevention of intraocular hypertension. The invention thus relates to the use of pharmaceutical compositions comprising antisecretory factors in the treatment and/or prevention of intraocular hypertension, which is preferably characterized by hampered outflow of body fluid resulting in elevated pressure in the eye. The invention provides for a novel approach for treating and/or preventing such a condition turning the intraocular pressure to an acceptable level, optionally 21 mm Hg, or less.06-25-2009
20090246147Delivery Of Antipsychotics Through An Inhalation Route - The present invention relates to the delivery of antipsychotics through an inhalation route. Specifically, it relates to aerosols containing antipsychotics that are used in inhalation therapy. In a method aspect of the present invention, an antipsychotic is delivered to a patient through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises an antipsychotic, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles with less than 5% antipsychotic drug degradation products. In a kit aspect of the present invention, a kit for delivering an antipsychotic through an inhalation route is provided which comprises: a) a thin coating of an antipsychotic composition and b) a device for dispensing said thin coating as a condensation aerosol.10-01-2009
20110268668PROCESS FOR NEBULIZING AQUEOUS COMPOSITIONS CONTAINING HIGHLY CONCENTRATED INSULIN - A process for nebulizing highly concentrated solutions of insulin for administration by inhalation.11-03-2011
20110268667Freshening Compositions Having A Malodor Control Component And Methods Thereof - A freshening composition having a malodor control component, about 1% to about 5% of low molecular weight monohydric alcohols, and an aqueous carrier are provided. The composition is essentially free of any material that would soil or stain fabric. The composition may be delivered to fabrics and/or air. The malodor control component may include an effective amount of volatile aldehydes and/or an acid catalyst.11-03-2011
20130095044USE OF STREPTOCOCCUS SALIVARIUS IN THE TREATMENT OF CHRONIC INFECTIONS OF THE RESPIRATORY TRACT - A new microbial strain of the species 04-18-2013
20130115173Stable Dermatological Aerosol Foams Utilizing Reactive Propellants - Described herein are chemically-stabile formulations comprising a reactive propellant. The formulations are delivered as an aerosol foam, and are suitable for topical application. The aerosol propellant may be a hydrofluoroolefin propellant. The emulsions or compositions may comprise reactive active agents, such as peroxides, retinoids, or quinones. Also described are methods of treating skin disorders, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive emulsion or aerosol composition.05-09-2013
20130101526Treatment Methods Using Disinfecting Compositions Containing a Polymer Complex of Organic Acid - The present invention provides compositions which not only effectively kill a broad spectrum of microorganisms present on surfaces on contact but continue to kill microorganisms for a period of time thereafter.04-25-2013
20080206158Benzoic Acid Ester Compounds, Compositions, Uses and Methods Related Thereto - Benzoic acid ester compounds of formula (I):08-28-2008
20080199410Pulmonary surfactant formulations and methods for promoting mucus clearance - Methods and compositions to enhance mucus clearance and to treat of pulmonary lung disorders such as cystic fibrosis are disclosed. The methods utilize pulmonary surfactants, alone or combined with hyperosmotic agents, administered to patients in an amount effective to enhance mucus clearance. The compositions comprise a pulmonary surfactant combined with an osmotically active agent.08-21-2008
20110223116APPARATUS AND METHOD FOR AEROSOL DELIVERY TO THE LUNGS OR OTHER LOCATIONS OF THE BODY - This disclosure relates to an apparatus useful for the delivery of aerosols, such as those containing drugs, to the lungs or other locations in the body. The disclosure also relates to methods of administering an aerosol to the lungs or other locations in the body of a patient.09-15-2011
20090185983AQUEOUS MEDICAMENT PREPARATIONS FOR THE PRODUCTION OF PROPELLANT GAS-FREE AEROSOLS - The present invention relates to pharmaceutical preparations in the form of aqueous solutions for the production of propellant-free aerosols.07-23-2009
20100291003HISTONE DEACETYLASE INHIBITORS - Novel compounds of the general formula (I), having histone deacetylase (HDAC) inhibiting enzymatic activity, their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. The present invention more particularly provides novel compounds of the general formula (I). Also included is a method for treatment of cancer, psoriasis, proliferative conditions and conditions mediated by HDAC, in a mammal comprising administering an effective amount of a novel compound of formula (I).11-18-2010
20090263334Cyclic Glycyl-2-Allyl Proline Improves Cognitive Performance in Impaired Animals - Embodiments of this invention provide methods for therapeutic use of cyclic G-2-Allyl Proline to treat cognitive disorders as well as manufacture of medicaments including tablets, capsules, injectable solutions that are useful for treatment of such conditions.10-22-2009
20120282189Improved Medicinal Aerosol Formulations - The present invention provides a medicinal aerosol suspension formulation for MDI administration, comprising: a) micronised pa-agonist; b) micronised corticosteroid; c) a siib-therapexrtic quantity of a moisture-scavenger excipient; and d) a HFA propellant; wherein (a), (b) and (c) and their respective relative amounts are selected such that they associate to form floccules having a density substantially the same as that of the HFA propellant.11-08-2012
20130183251PENETRATING PHARMACEUTICAL FOAM - The invention relates to an alcohol-free cosmetic or pharmaceutical foam composition comprising water, a hydrophobic solvent, a surface-active agent, a gelling agent, an active component selected from the group of urea, hydroxy acid and a therapeutic enhancer and a propellant. The foam further comprises active agents and excipients with therapeutic properties having enhanced skin penetration.07-18-2013
20110293536BUCCAL, POLAR AND NON-POLAR SPRAY CONTAINING ZOLIPIDEM - Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide zolpidem for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, zolpidem, and optional flavoring agent; formulation II: aqueous polar solvent, zolpidem, optionally flavoring agent, and propellant; formulation III: non-polar solvent, zolpidem, and optional flavoring agent; formulation IV: non-polar solvent, zolpidem, optional flavoring agent, and propellant; formulation V: a mixture of a polar solvent and a non-polar solvent, zolpidem, and optional flavoring agent; formulation VI: a mixture of a polar solvent and a non-polar solvent, zolpidem, optional flavoring agent, and propellant.12-01-2011
20110311462COMPOSITIONS FOR TREATMENT OF EAR DISORDERS AND METHODS OF USE THEREOF - The present invention relates to compositions and methods useful for the treatment of ear disorders, administered to a treated ear in the form of a foam or a mousse. Administering a medicament in such forms will increase the residence time of the medicament in the ear canal, provide relatively uniform distribution of the composition, and can increase the penetration of the active pharmaceutical ingredient in the affected area, may release active substances slowly, enhance treatment effectiveness, increase compliance and is more convenient to use than currently available ear medications. The administration in the form of a foam or a mousse may preferably be provided as a metered dose, of a volume suitable to fill the ear canal.12-22-2011
20110311461ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF - The present invention relates to alkaloid aminoester compounds which act as muscarinic receptor antagonists, processes for their preparation, compositions comprising them, and therapeutic uses thereof.12-22-2011
20110311460Aerosol odor eliminating compositions containing alkylene glycol(s) - Aerosol odor eliminating compositions are described which are aqueous based and include at least one alkylene glycol, at least one surfactant wherein one or more of the at least one surfactant has an HLB of about 7 to about 20, compressed gas propellant, at least one fragrance, a buffering system and water. The composition excludes inclusion of a low molecular weight monohydric. The compositions have a volatile organic content (VOC) of less than 5.0% of the total composition based on 100 wt. %, or alternatively, a VOC of less than 0.1% as to the total composition based on 100 wt. % in absence of the wt. % of the active fragrant material of the fragrance. The compositions additionally have a consistent spray rate at multiple pressure ranges.12-22-2011
20130189194COMBINATIONS OF MEDICAMENTS FOR THE TREATMENT OF RESPIRATORY DISEASES - A pharmaceutical composition comprising: 07-25-2013
20130189195DICARBOXYLIC ACID FOAMABLE VEHICLE AND PHARMACEUTICAL COMPOSITIONS THEREOF - The present invention teaches a foamable pharmaceutical carrier comprising a benefit agent, selected from the group consisting of a dicarboxylic acid and a dicarboxylic acid ester; a stabilizer selected from the group consisting of at least one surface-active agent; at least one polymeric agent and mixtures thereof; a solvent selected from the group consisting of water, a hydrophilic solvent, a hydrophobic solvent, a potent solvent, a polar solvent, a silicone, an emollient, and mixtures thereof, wherein the benefit agent, stabilizer and solvent are selected to provide a composition that is substantially resistant to aging and to phase separation and or can substantially stabilize other active ingredients. The invention further relates to a foamable composition further containing a liquefied hydrocarbon gas propellant.07-25-2013
20080311051Caspase-2 Inhibitors And Their Biological Applications - The invention relates to selective new caspase-2 inhibitors that recognize caspase-2 and prevent and block its activity based on the following backbone: 2-Quinolinylcarbonyl-L-Valinyl-L-Aspartyl (methyl ester)-L-Vanilyl-L-Alaninyl-L-Aspartyl (methyl ester) 2,6-difluorophenyl ester (SEQ1) and derivatives thereof, SEQ 1 corresponding to formulae (Ia) or (Ib). Application of said inhibitors for preventing and treating diseases involving caspase-2.12-18-2008
20120027692PYRROLOPYRIMIDINEDIONE AND ITS THERAPEUTIC USE - The compound of formula (I) is an inhibitor of human neutrophil elastase, useful for inhalation treatment of pulmonary inflammation.02-02-2012
20120027691Cinnamic Acid-Based Oligomers and Uses Thereof - Cinnamic acid-based oligomers and therapeutic uses thereof are provided. The oligomers are used as anti-inflammation agents, inhibitors of elastase and anti-oxidants, and in some cases (e.g. the treatment of lung disorders such as lung cancer) all three activities are simultaneously beneficial. Subsets of the oligomers (e.g. β-O4 and β-5 trimers and tetramers) are used as anticoagulants.02-02-2012
20120058057Anti-dandruff Agents - The present invention relates to special ammonium carboxylates, their synthesis and application, particularly as anti-dandruff agents.03-08-2012
20120070384TOPICAL ANTIFUNGAL COMPOSITION - A topical, foamable composition is provided that includes at least one antifungal agent that is able to penetrate the upper layers of skin and is retained in or on an area to be treated for a prolonged period of time, and that has a residual non-volatile component content less than 25%. In addition, a method of treating fungal diseases including jock itch, tinea, dandruff and sebborheic dermatitis is provided, and includes applying to the affected area of patient requiring such treatment an antifungal composition.03-22-2012
20120082627OTIC FOAM FORMULATIONS - The present invention relates to foamable otic pharmaceutical compositions comprising fluoroquinolones and methods of preparing same. Particularly, the present invention relates to pharmaceutical compositions comprising oil-in-water emulsions comprising fluoroquinolones and gas propellants, administered to the ear as foam for treating ear disorders.04-05-2012
20120093740PEPTIDE FRAGMENTS FOR INDUCING SYNTHESIS OF EXTRACELLULAR MATRIX PROTEINS - Short biologically active tetrapeptides are disclosed that are comprised of the sequences GxxG and PxxP where G (glycine) and P (proline) are maintained and x is a variable amino acid. The peptides can be used singly or in combination to stimulate production of extracellular matrix proteins in skin. A rapid, low-cost method of producing heterogenous formulations of tetrapeptides is disclosed.04-19-2012
20120093739METHOD FOR TREATING HAIR GROWTH DISORDERS, SUCH AS FEMALE PATTERN ALOPECIA, AND COMPOSITIONS USEFUL THEREFORE - The invention relates to formulations useful in treating hair disorders, improving the health of hair, increasing hair growth, and in increasing the niacin content of hair follicles. Nicotinic acid alkyl esters having a straight chain alkyl group of from 1 to 22 methylene units, preferably from 6 to 16 methylene units, and most preferably from 8 to 14 methyl units, may be used, alone or in combinations for treating these conditions.04-19-2012

Patent applications in class Organic pressurized fluid

Patent applications in all subclasses Organic pressurized fluid